Note: Descriptions are shown in the official language in which they were submitted.
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
NOVEL COMPOUNDS
Field of the Invention
The present invention relates to compounds that bind to and modulate the
activity of
neuronal nicotinic acetylcholine receptors, to novel salts thereof, to
processes for preparing
these compounds, to pharmaceutical compositions containing these compounds,
and to
methods of using these compounds for treating a wide variety of conditions and
disorders,
including those associated with dysfunction of the central nervous system
(CNS).
Background of the Invention
The therapeutic potential of compounds that target neuronal nicotinic
receptors (NNRs),
also known as nicotinic acetylcholine receptors (nAChRs), has been the subject
of several
reviews. See, for example, Breining et al., Ann. Rep. Med. Chem. 40: 3 (2005),
Hogg and
Bertrand, Curr. Drug Targets: CNS Neurol. Disord. 3: 123 (2004). Among the
kinds of
indications for which NNR ligands have been proposed as therapies are CNS
disorders
mentioned below. There exists a heterogeneous distribution of nAChR subtypes
in both the
central and peripheral nervous systems. For instance, the nAChR subtypes which
are
predominant in vertebrate brain are a4p2, a7, and a3R2, whereas those which
predominate at
the autonomic ganglia are a3P4 and those of neuromuscular junction are al (31
yb and al I3l yE.
A limitation of some nicotinic compounds is that they are associated with
various
undesirable side effects due to non-specific binding to multiple nAChR
subtypes. For example,
binding to and stimulation of muscle and ganglionic nAChR subtypes can lead to
side effects
which can limit the utility of a particular nicotinic binding compound as a
therapeutic agent.
The commercial development of a drug candidate involves many steps, including
the
development of a cost effective synthetic method that is adaptable to a large
scale
manufacturing process. Commercial development also involves research regarding
salt forms
of the drug substance that exhibit suitable purity, chemical stability,
pharmaceutical properties,
and characteristics that facilitate convenient handling and processing.
Furthermore,
compositions containing the drug substance should have adequate shelf life.
That is, they
should not exhibit significant changes in physicochemical characteristics such
as, but not limited
to, chemical composition, water content, density, hygroscopicity, stability,
and solubility upon
storage over an appreciable period of time. Additionally, reproducible and
constant plasma
concentration profiles of drug upon administration to a patient are also
important factors.
1
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Solid salt forms are generally preferred for oral formulations due to their
tendency to
exhibit these properties in a preferential way; and in the case of basic
drugs, acid addition salts
are often preferred salt. However, different salt forms vary greatly in their
ability to impart these
properties and such properties cannot be predicted with reasonable accuracy.
For example,
some salts are solids at ambient temperatures, while other salts are liquids,
viscous oils, or
gums at ambient temperatures. Furthermore, some salt forms are stable to heat
and light under
extreme conditions and others readily decompose under much milder conditions.
Salts also
vary greatly in their hygroscopicity, the less hygroscopic being more
advantageous. Thus, the
development of a suitable acid addition salt form of a basic drug for use in a
pharmaceutical
composition is a highly unpredictable process.
Racemic 5-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine,
its
synthesis, and its hemi-galactarate salt form are disclosed in WO 04/078752
which is
incorporated by reference, and its counterparts. Because of the advantageous
pharmacological
properties of a single enantiomer over its racemate, there is a need for a
stereospecific
synthesis, preferably a process suitable for large-scale production.
Furthermore, there is a
need for salt forms that display improved properties, such as for example
purity, stability,
solubility, and bioavailability. Preferential characteristics of these novel
salt forms include those
that would increase the ease or efficiency of manufacture of the active
ingredient and its
pharmaceutical composition into a commercial drug product and improved
stability of the drug
over a prolonged period of time.
Summary of the Invention
One aspect of the present invention is (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine mono-L-malate or a hydrate or solvate
thereof. Another
aspect is (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine hemi-galactarate
or a hydrate or solvate thereof. Another aspect is (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine oxalate or a hydrate or solvate thereof.
Another aspect is (R)-
3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-
toluoyl-D-tartrate or a
hydrate or solvate thereof.
One aspect of the present invention is (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt
thereof substantially
free of (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine. In one
embodiment, (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine is present in
2
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
an amount of less than 25% by weight. In one embodiment, (S)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine is present in an amount of less than 15% by
weight. In one
embodiment, (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine is present in
an amount of less than 5% by weight. In one embodiment,
(S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine is
present in an amount of
less than 2% by weight. In one embodiment, (S)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine is present in an amount of less than 1% by
weight. In one
embodiment, the (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine is free of
a significant amount of (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine.
One aspect of the present invention is a pharmaceutical composition comprising
a
compound as herein disclosed and one or more pharmaceutically acceptable
adjuvant, carrier,
or excipient. In one embodiment, the pharmaceutical composition further
comprises one or more
additional therapeutic agent.
One aspect of the present invention includes a compound (R)-3-((E)-2-
(Pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or hemi-
galactarate or oxalate or di-
p-toluoyl-D-tartrate for use as a medicament in treating a NNR mediated
disorder.
Another aspect includes a method for the treatment or prevention of a NNR
mediated
disorder comprising administering to a mammal in need of such treatment, a
therapeutically
effective amount of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine or a
pharmaceutically acceptable salt thereof.
Another aspect includes use of a compound (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-
5-
(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt
thereof in the
preparation of a medicament for the treatment of a NNR mediated disorder.
In one embodiment of the aforementioned compound, method, or use, the disorder
is
selected from the group consisting of CNS disorders, inflammation,
inflammatory response
associated with bacterial and/or viral infection, pain, metabolic syndrome,
autoimmune
disorders. In one embodiment, the CNS disorder is selected from cognitive
dysfunction in
schizophrenia (CDS), Alzheimers Disease (AD), attention deficit disorder
(ADD), pre-senile
dementia (early onset of Alzheimer's Disease), dementia of the Alzheimer's
type, mild cognitive
impairment, age associated memory impairment and attention deficit
hyperactivity disorder
(ADHD).
Another aspect of the present invention includes an administration regimen of
a
pharmaceutical composition comprising administering (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
3
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(tetrahydropyran-4-yloxy)pyridine, or a pharmaceutically acceptable salt
thereof in amounts of
between 7 to 2200 pg/kg.
In the aspects and embodiments, another embodiment includes where the (R)-3-
((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine is provided as the
mono-L-malate,
hemi-galactarate, oxalate, or di-p-toluoyl-D-tartrate salt thereof.
Another aspect includes novel intermediates, including diethyl (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)malonate; (R)-2-(1-(tent-
butoxycarbonyl)pyrrolidin-3-yl)malonic
acid; tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate; and tent-
butyl (R)-3-(2-
iodoethyl)pyrrolidine-1 -carboxylate.
Another aspect includes a method of making (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine through the intermediacy of one or more of
diethyl (R)-2-(1-
(tert-butoxycarbonyl)pyrrolidin-3-yl)malonate, (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-
yl)malonic acid, tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate,
and tert-butyl (R)-3-
(2-iodoethyl)pyrrolidine-1 -carboxylate.
Another aspect includes a method of making tert-butyl (R)-3-vinylpyrrolidine-1-
carboxylate through the intermediacy of one or more of diethyl (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)malonate, (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)malonic
acid, tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate, and tert-
butyl (R)-3-(2-
iodoethyl)pyrrolidine-1 -carboxylate.
Another aspect includes a method of purifying (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine, with respect to isomeric (R)-3-((Z)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine and (R)-3-(1-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine, by conversion to the oxalate salt and re-generation of the
free base.
Combinations of aspects and embodiments form further embodiments of the
present
invention.
Brief Description of the Figures
Figure 1 depicts novel object recognition (NOR) vs. dose for (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof, hereinafter
referred to as
Compound A. A statistically significant effect was observed for doses as low
as 0.004 M/kg.
Figure 2 depicts novel object recognition (NOR) vs. time for (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof, Compound A, a
dose at 0.004
M/kg. A statistically significant effect was observed out to 8h after dosing.
4
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Figure 3 depicts results of Radial Arm Maze (RAM) Studies in which (R)-3-((E)-
2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof,
Compound A,
overcomes scopolamine induced deficits in the radial arm maze.
Detailed Description
Definitions
The following definitions are meant to clarify, but not limit, the terms
defined. If a
particular term used herein is not specifically defined, such term should not
be considered
indefinite. Rather, terms are used within their accepted meanings.
As used herein, the term "compound(s)" may be used to mean the free base form,
or
alternatively, a salt form of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine
(Formula I), depending on the context, which will be readily apparent. Those
skilled in the art
will be able to distinguish the difference.
As used herein, the phrase "pharmaceutically acceptable" refers to carrier(s),
diluent(s), excipient(s) or salt forms of the compound of Formula I that are
compatible with the
other ingredients of the composition and not deleterious to the recipient of
the pharmaceutical
composition.
As used herein, the phrase "pharmaceutical grade" refers to a compound or
composition
of a standard suitable for use as a medicine. With reference to the discussion
herein,
pharmaceutical grade compounds of the present invention, particularly salt
forms thereof,
display appropriate properties, including purity, stability, solubility, and
bioavailability for use in a
drug product. Preferential characteristics include those that would increase
the ease or
efficiency of manufacture of the active ingredient and its composition into a
commercial drug
product. Furthermore, pharmaceutical grade compounds of the present invention
may be
synthesized using a stereospecific synthesis that is scalable to a large-scale
production, namely
displaying adequate purity and yield.
As used herein, the term "pharmaceutical composition" refers to a compound of
the
present invention optionally admixed with one or more pharmaceutically
acceptable carriers,
diluents, or excipients. Pharmaceutical compositions preferably exhibit a
degree of stability to
environmental conditions so as to make them suitable for manufacturing and
commercialization
purposes.
As used herein, the terms "effective amount", "therapeutic amount", or
"effective dose"
refer to an amount of the compound of the present invention sufficient to
elicit the desired
5
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
pharmacological or therapeutic effects, thus resulting in effective prevention
or treatment of a
disorder. Prevention of the disorder may be manifested by delaying or
preventing the
progression of the disorder, as well as the onset of the symptoms associated
with the disorder.
Treatment of the disorder may be manifested by a decrease or elimination of
symptoms,
inhibition or reversal of the progression of the disorder, as well as any
other contribution to the
well being of the patient.
As will be discussed in more detail below and with reference to Figures 1 and
2, a
statistically significant effect is observed for doses of the compound of
Formula I, or a
pharmaceutically acceptable salt thereof, as low as 0.004 pM/kg, including
effects observed out
to 8 h after dosing. The effective dose can vary, depending upon factors such
as the condition
of the patient, the severity of the symptoms of the disorder, and the manner
in which the
pharmaceutical composition is administered. Thus, as used herein, the
effective dose may be
less than 100 mg, in another embodiment less than 50 mg, in another embodiment
less than 10
mg, or in another embodiment less than 1 mg. These effective doses typically
represent the
amount administered as a single dose, or as one or more doses administered
over a 24 h
period.
As used herein, the phrase "substantially' or 'sufficiently' quality, purity
or pure, includes
greater than 20%, preferably greater than 30%, and more preferably greater
than 40% (e.g.
greater than any of 50, 60, 70, 80, or 90%) quality or purity.
The term "stability" as defined herein includes chemical stability and solid
state stability,
where the phrase "chemical stability" includes the potential to store salts of
the invention in an
isolated form, or in the form of a pharmaceutical composition in which it is
provided in admixture
with pharmaceutically acceptable carriers, diluents, excipients, or adjuvants,
such as in an oral
dosage form, such as a tablet, capsule, or the like, under normal storage
conditions, with an
insignificant degree of chemical degradation or decomposition, and the phrase
"solid state
stability", includes the potential to store salts of the invention in an
isolated solid form, or in the
form of a solid pharmaceutical composition in which it is provided in
admixture with
pharmaceutically acceptable carriers, diluents, excipients, or adjuvants, such
as in an oral
dosage form, such as a tablet, capsule, or the like, under normal storage
conditions, with an in-
significant degree of solid state transformation, such as crystallization,
recrystallization, solid
state phase transition, hydration, dehydration, solvation, or desolvation.
Examples of "normal storage conditions" include one or more of temperatures of
between -80 C and 50 C, preferably between 0 C and 40 C and more
preferably ambient
6
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
temperatures, such as 15 C to 30 C, pressures of between 0.1 and 2 bars,
preferably at
atmospheric pressure, relative humidity of between 5 and 95%, preferably 10 to
60%, and
exposure to 460 lux or less of UV/visible light, for prolonged periods, such
as greater than or
equal to six months. Under such conditions, salts of the invention may be
found to be less than
5%, more preferably less than 2%, and especially less than 1 %, chemically
degraded or
decomposed, or solid state transformed, as appropriate. The skilled person
will appreciate that
the above-mentioned upper and lower limits for temperature, pressure, and
relative humidity
represent extremes of normal storage conditions, and that certain combinations
of these
extremes will not be experienced during normal storage (e.g. a temperature of
50 C and a
pressure of 0.1 bar).
As used herein, the term "disorder", unless stated otherwise, means any
condition,
dysfunction, or disease associated with NNR receptor activity.
Compounds
One embodiment of the present invention relates to (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine (Formula I) or a pharmaceutically acceptable
salt thereof.
H
N
O
N 0
Formula I
As will be appreciated by those skilled in the art, different naming
conventions may name a
compound differently. Thus, Compound A may be named (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or, alternatively, (R)-3-(2-pyrrolidin-3-yl)-
vinyl)-5-((tetrahydro-
2H-pyran-4-yl)oxy)pyridine. Such naming conventions should not be used to
introduce
ambiguity to this specification.
In one embodiment, the compound of Formula I or a pharmaceutically acceptable
salt
thereof is substantially pure. In one embodiment, the compound of Formula I or
a
pharmaceutically acceptable salt thereof is substantially free of (S)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine. In one embodiment, the compound
of Formula I or
a pharmaceutically acceptable salt thereof is present in an amount of about
75% by weight
compared to (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine, preferably
7
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
greater than 85% by weight, more preferably greater than 95% by weight, more
preferably
greater than 98% by weight, and most preferably 99% by weight or greater. One
embodiment
relates to 100% pure (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine
(Formula I).
Process
One embodiment of the present invention relates to a method for the
preparation of (R)-
3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
pharmaceutically
acceptable salt thereof substantially free of (S)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine by weight. Another embodiment of the present
invention
relates to a method for the preparation of (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-
4-yloxy)pyridine or a pharmaceutically acceptable salt thereof containing less
than 25%,
preferably less than 15%, more preferable less than 5%, even more preferably
less than 2%,
and most preferably less than 1 % of (S)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine by weight, without the use of a chiral chromatographic
separation step. In one
embodiment of the present invention, a method for the manufacture of
substantially pure (R)-3-
((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine is
provided, without reliance
upon chromatographic separation.
General Synthetic Methods
Racemic 3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
can be
synthesized as reported in PCT WO2004/078752, herein incorporated by
reference, using a
palladium catalyzed coupling of tert-butyl 3-vinylpyrrolidine-1-carboxylate
with the 3-bromo-
5-(tetrahydro-2H-pyran-4-yloxy)pyridine, followed by removal of the tert-
butoxycarbonyl
protecting group. In the racemic synthesis, the requisite tert-butyl 3-
vinylpyrrolidine-1-
carboxylate was produced by treating tert-butyl 3-formylpyrrolidine-1-
carboxylate with
methylenetriphenylphosphorane (Wittig reagent). While tert-butyl 3-
formylpyrrolidine-1-
carboxylate can be made by several methods, it was not an ideal intermediate
for a single
enantiomer synthesis, in that it is susceptible to racemization during the
Wittig reaction.
Thus, a new synthetic route, one characterized by stereochemical fidelity, was
devised.
The compounds may be prepared according to the following methods using
commercially available starting materials and reagents.
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine may
be prepared
via palladium catalyzed coupling of tert-butyl (R)-3-vi nylpyrrolidine-1-
carboxylate (compound 9)
and 3-bromo-5-(tetrahydro-2H-pyran-4-yloxy)-pyridine (compound 12) as outlined
in Scheme 3.
8
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
The preparation of compound 9 is outlined in Scheme 1. Commercially available
tert-
butyl (R)-3-hydroxypyrrolidine-1-carboxylate (compound 1) is treated with
methanesulfonyl
chloride to give tent-butyl (R)-3-(methylsulfonyloxy)pyrrolidine-1-carboxylate
(compound 2),
which then is reacted with diethylmalonate and a suitable base (e.g.,
potassium tert-butoxide or
sodium ethoxide) to give diethyl (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-
yl)malonate
(compound 3) with inverted stereochemistry around the chiral carbon.
Suitable solvents for these reactions may be selected from the group of
toluene, xylenes,1-
methyl-2-pyrrolidi none, dimethylformamide, dimethylacetamide, ethanol, tert-
butanol,
tetrahydrofuran, 1,2-dimethoxyethane, dioxane, and mixtures thereof. In one
embodiment the
solvent for the methanesulfonic ester formation toluene, and the solvent for
the malonate
displacement is 1-methyl-2-pyrrolidinone. In another embodiment the solvent
for the malonate
displacement is ethanol. Suitable bases for these reactions may be selected
from the group of
triethylamine, diethylisopropylamine, diisopropylethylamine, potassium tert-
butoxide, sodium
metal, sodium hydride, sodium ethoxide, potassium hydride and lithium hydride.
In one
embodiment the base for the methanesulfonic ester formation is triethylamine,
and the base for
the malonate displacement is potassium tert-butoxide. In another embodiment.
the base for the
malonate displacement is sodium ethoxide.
Hydrolysis of diester 3 with aqueous potassium hydroxide yields (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)malonic acid (compound 4), which is
decarboxylated to afford (R)-
2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (compound 5). Suitable
solvents for these
reactions may be selected from the group of water, ethanol, tetrahydrofuran,
dimethylformamide, dimethylacetamide, 1,2-dimethoxyethane, dioxane, 1-methyl-2-
pyrrolidinone, toluene, dimethylsulfoxide, and mixtures thereof. In one
embodiment the solvent
for the ester hydrolysis is aqueous tetrahydrofuran, and the solvent for the
decarboxylation is 1-
methyl-2-pyrrolidinone. In another embodiment the solvent for the ester
hydrolysis is ethanol,
and the solvent for the decarboxylation is a mixture of dimethylsufloxide and
toluene. Suitable
bases for the hydrolysis reaction may be selected from the group of potassium
hydroxide,
sodium hydroxide, potassium carbonate, sodium carbonate, barium hydroxide and
cesium
carbonate. In one embodiment the base is potassium hydroxide.
Reduction of compound 5 gives tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-
carboxylate
(compound 6), which may be reacted with methanesulfonyl chloride and then
sodium iodide to
give tert-butyl (R)-3-(2-(methylsulfonyloxy)ethyl)pyrrolidine-1-carboxylate
(compound 7) and tert-
butyl (R)-3-(2-iodoethyl)pyrrolidine-1-carboxylate (compound 8), respectively.
Suitable solvents
9
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
for the reduction reaction may be selected from the group of tetrahydrofuran,
ether, dioxane,
1,2-dimethoxyethane, and mixtures thereof. In one embodiment the solvent is
tetrahydrofuran.
Suitable reducing agents may be selected from the group of borane, diborane,
borane-
tetrahydrofuran complex, borane-dimethyl ether complex and borane-
dimethylsulfide complex.
Suitable solvents for the methanesulfonic ester formation may be selected from
the group of
toluene, xylenes, ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, and
mixtures thereof.
In one embodiment the solvent for the methanesulfonic ester formation is
toluene. Suitable
bases for the methanesulfonic ester formation may be selected from the group
of triethylamine,
diethylisopropylamine and diisopropylethylamine. In one embodiment the base
for the
methanesulfonic ester formation is triethylamine. Suitable solvents for the
iodide displacement
may be selected from the group of 1-methyl-2-pyrrolidinone, dimethylformamide,
dimethylacetamide, ethanol, tert-butanol, tetrahydrofuran, 1,2-
dimethoxyethane, dioxane,
dimethylsulfoxide, and mixtures thereof. In one embodiment the solvent for the
iodide
displacement is 1,2-dimethoxyethane.
Finally, treatment of compound 8 with potassium tert-butoxide gives of
compound 9.
Suitable solvents for this reaction may be selected from the group of 1,2-
dimethoxyethane, 1-
methyl-2-pyrrolidi none, dimethylformamide, dimethylacetamide, ethanol,
tetrahydrofuran,
dioxane and mixtures thereof. In one embodiment the solvent is 1,2-
dimethoxyethane. Suitable
bases for this reaction may be selected from the group of potassium tert-
butoxide, sodium
ethoxide and diazabicycloundecane. In another embodiment the base is potassium
tert-
butoxide.
One embodiment of the invention relates to a process for the preparation of
compound 9
using the reaction steps as outlined in Scheme 1 and in the discussion above.
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
COZEt\ CO2H
OH OMs ?-CO2Et ~-CO2H "-CO2H
N
N N N N
boc boc boc boc boc
1 2 3 4 5
OH OMs
N N N
boc boc boc
boc
6 7 8 9
Scheme I
The preparation of 3-bromo-5-(tetrahydro-2H-pyran-4-yloxy)-pyridine (compound
12) is
outlined in Scheme 2. Coupling of 3-bromo-5-hydroxypyridine (compound 10) with
4-
hydroxytetrahydro-2H-pyran (compound 11) gives compound 12. Suitable
conditions for the
coupling include those in which a phosphine (e.g., triphenylphosphine) and an
azo compound
(e.g., diethyl azodicarboxylate, also known as DEAD) are used, in an inert
solvent, to effect the
coupling (e.g., toluene). Alternately, other conditions, in which the oxo
anion of 3-bromo-5-
hydroxypyridine displaces a leaving group from the 4-position of
tetrahydropyran, may be
employed.
One embodiment of the invention relates to a process for the preparation of
compound
12 using the reaction steps as outlined in Scheme 2 and above.
HO Br OH O Br
+ > ra ,~
O 0
N N
10 11 12
Scheme 2
The final steps in the preparation of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine (free base form) is illustrated in Scheme 3.
Compounds 9 and
12 are coupled via a palladium acetate mediated coupling reaction to afford
tert-butyl (R)-(E)-3-
(2-(5-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl)vinyl)pyrrolidine-1-
carboxylate (also known as
11
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(R)-5-(1-(tert-butoxycarbonyl)-(E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine,
compound 13), which is de-protected to give (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine (compound 14). Suitable solvents for the
palladium-catalyzed
coupling reaction may be selected from the group of 1-methyl-2-pyrrolidinone,
dimethylformamide, dimethylacetamide and acetonitrile. In one embodiment the
solvent is 1-
methyl-2-pyrrolidinone. Suitable bases for the palladium catalyzed coupling
reaction may be
selected from the group of triethylamine, diethylisopropylamine,
diisopropylethylamine. In one
embodiment the base is diisopropylethylamine. Suitable phosphine ligands for
the palladium
catalyzed coupling reaction may be selected from the group of tri-n-
butylphosphine, tri-tert-
butylphosphine, tricyclohexylphosphine, triphenylphosphine and tri-o-
tolylphosphine. In one
embodiment the phosphine ligand is tricyclohexylphosphine. Suitable palladium
catalysts for
the palladium catalyzed coupling reaction may be selected from the group of
palladium acetate,
palladium chloride and dipalladium tris(dibenzylacetone). In one embodiment
the palladium
catalyst is palladium acetate. Suitable solvents for the de-protection
reaction may be selected
from the group of water, dichloromethane, chloroform and dichloroethane. In
one embodiment
the solvent is dichloromethane. In another embodiment the solvent for the de-
protection
reaction is water.
Suitable acids for the de-protection reaction may be selected from the group
of trifluoroacetic
acid, hydrochloric acid and sulfuric acid. In one embodiment the acid is
trifluoroacetic acid.
Br O
0-C
-00 No .... 0
0 -
I N Boc
Boc N
9 12 13
00
HN /
_0
N
14
Scheme 3
One embodiment of the invention relates to a process for the preparation of
compound
14 using the reaction steps as outlined above in Schemes 1, 2 and 3. The
invention further
relates to a process for the preparation of the salt form of (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
12
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(tetrahydropyran-4-yloxy)pyridine malate comprising the additional step of
reacting the free base
with L-malic acid in a mixture of 2-propanol and isopropyl acetate or other
suitable solvent as
described below.
Another embodiment of the invention relates to the formation of the oxalate
salt of
compound 14 and the use of the oxalate salt as a purification intermediate in
the production of
compound 14. The palladium catalyzed coupling of compounds 9 and 12 produces a
mixture of
materials in which compound 13 predominates, typically representing 75-80% of
the coupling
products. The remaining coupling products include the corresponding Z isomer,
tert-butyl (R)-
(Z)-3-(2-(5-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl)vinyl)pyrrolidine-1-
carboxylate, and a so-
called "exo" isomer, tert-butyl (R)-3-(1-(5-(tetrahydro-2H-pyran-4-
yloxy)pyridin-3-
yl)vinyl)pyrrolidine-1-carboxylate, typically representing -5% and up to 20%
of the coupling
products respectively. Removal of these minor isomers from the major, desired
isomer was
unexpectedly and conveniently accomplished by de-protection of the mixture of
isomers,
followed by conversion of the free base to the oxalate salt. Initial
precipitation of the oxalate salt
in water/2-propanol mixtures, for example, gives compound 14 in which the
isomeric impurities
are reduced to <1 % each or better. Further purification can be accomplished
by
recrystallization.
Examples of compounds of the present invention which are labeled with a
radioisotope appropriate to various diagnostic uses are for example, 11C- or
18 F-labeled
analogs of compound 14 which would be suitable for use in positron emission
tomography.
Unless otherwise stated, structures depicted herein are also meant to include
compounds which differ only in the presence of one or more isotopically
enriched atoms. For
example, compounds having the present structure except for the replacement of
a hydrogen
atom by deuterium or tritium, or the replacement of a carbon atom by 13C or
14C, or the
replacement of a nitrogen atom by 15N, or the replacement of an oxygen atom
with 170 or180 are
within the scope of the invention. Such isotopically labeled compounds are
useful as research
or diagnostic tools.
In all of the examples described below, protecting groups for sensitive or
reactive groups
are employed where necessary in accordance with general principles of
synthetic chemistry.
Protecting groups are manipulated according to standard methods of organic
synthesis (T. W.
Green and P. G. M. Wuts, Protecting Groups in Organic Synthesis, 3rd Edition,
John Wiley
& Sons, New York (1999)). These groups are removed at a convenient stage of
the compound
synthesis using methods that are readily apparent to those skilled in the art.
The selection of
13
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
processes as well as the reaction conditions and order of their execution
shall be consistent with
the preparation of compounds of the present invention.
The present invention also provides a method for the synthesis of novel
compounds
useful as intermediates, such as diethyl (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)maIonate
(compound 3), (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-yl)malonic acid
(compound 4), tert-butyl
(R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate (compound 6), and tert-butyl
(R)-3-(2-
iodoethyl)pyrrolidine-1-carboxylate (compound 8).
Salt Forms
One aspect of the present invention relates to novel salt forms of (R)-3-((E)-
2-(pyrrolidin-
3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine. (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine in the free base form is a viscous oil with
limited water
solubility. However, the free base may react with both inorganic and organic
acids to make acid
addition salts that have physical properties that are advantageous for the
preparation of
pharmaceutical compositions such as crystallinity, water solubility, and
stability toward chemical
degradation.
The present invention relates to pharmaceutically acceptable salts of (R)-3-
((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine. Examples of
suitable
pharmaceutically acceptable salts include inorganic acid addition salts such
as chloride,
bromide, sulfate, phosphate, and nitrate; organic acid addition salts such as
acetate,
galactarate, propionate, succinate, lactate, glycolate, malate, tartrate,
citrate, maleate, fumarate,
methanesulfonate, p-toluenesulfonate, and ascorbate; salts with acidic amino
acid such as
aspartate and glutamate; alkali metal salts such as sodium salt and potassium
salt; alkaline
earth metal salts such as magnesium salt and calcium salt; ammonium salt;
organic basic salts
such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt,
dicyclohexylamine
salt, and N,N'-dibenzylethylenediamine salt; and salts with basic amino acid
such as lysine salt
and arginine salt. The salts may be in some cases hydrates or solvates, such
as ethanol
solvates.
One embodiment of the present invention relates to acid addition salts of (R)-
3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine wherein the acid
is selected from
hydrochloric acid, methane sulphonic acid, maleic acid, phosphoric acid, 1-
hydroxy-2-naphthoic
acid, malonic acid, L-tartaric acid, fumaric acid, citric acid, L-malic acid,
R-mandelic acid, S-
mandelic acid, succinic acid, 4-acetamidobenzoic acid, adipic acid, galactaric
acid, di-p-toluoyl-
D-tartaric acid, oxalic acid, D-glucuronic acid, 4-hydroxybenzoic acid, 4-
methoxybenzoic acid,
14
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(1S)-(+)-10-camphorsulfonic acid, (1R,3S)-(+)-camphoric acid, and p-
toluenesulfonic acid. The
present invention also includes hydrates and solvates of these salt forms.
The stoichiometry of the salts comprised in the present invention may vary.
For
example, it is typical that the molar ratio of acid to (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine is 1:2 or 1:1, but other ratios, such as
3:1, 1:3, 2:3, 3:2 and
2:1, may be possible and are likewise included in the scope of the present
invention
Depending upon the manner by which the salts described herein are formed, the
salts
may have crystalline structures that occlude solvents that are present during
salt formation.
Thus, the salts may occur as hydrates and other solvates of varying
stoichiometry of solvent
relative to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetra hydropyran-4-
yloxy)pyridine.
In one embodiment of the present invention, the salt has a stoichiometry of
acid to (R)-3-
((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine of 1:2. In
another embodiment,
the salt has a stoichiometry of acid to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine of 1:1.
Another embodiment of the present invention relates to (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or a hydrate or
solvate thereof.
Another embodiment of the present invention relates to (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine hemi-galactarate or a hydrate or
solvate thereof.
Another embodiment of the present invention relates to (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine oxalate or a hydrate or solvate
thereof.
Another embodiment of the present invention relates to (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-toluoyl-D-tartrate or a
hydrate or solvate
thereof.
One embodiment of the present invention relates to the following salts of (R)-
3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine;
4-Acetamidobenzoic
Adipic
(1 R,3S)-(+)-Camphoric
(1 S)-(+)-1 O-Camphorsulfonic
Citric
Fumaric
D-glucuronic
Hydrochloric
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
4-Hydroxybenzoic
1 -Hydroxy-2-naphthoic (Xinafoic)
Maleic
L-Malic
Malonic
(R)-Mandelic
(S)-Mandelic
Methanesulfonic
4-Methoxybenzoic
Phosphoric
Succinic
L-Tartaric
p-Toluenesulfonic. H2O
or a hydrate or solvate thereof.
A further aspect of the present invention relates to processes for the
preparation of the
salts. The salts may be obtained by crystallization under controlled
conditions.
The invention also relates to a process for the preparation (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine salt forms comprising the
following steps:
(i) mixing the free base, or a solution of the free base of substantially pure
(R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine in a suitable
solvent, with any of the
acids mentioned above in pure form or as a solution of any of the acids in a
suitable solvent,
typically 0.5 to 1 equivalents of the acid;
(ii)(a) cooling the resulting salt solution if necessary to cause
precipitation, or
(ii)(b) adding a suitable anti-solvent to cause precipitation, or
(ii)(c) evaporating the solvent and adding and new solvent and repeating
either steps (ii)(a) or
step (ii)(b); and
(iii) filtering and collecting the salt.
The stoichiometry, solvent mix, solute concentration, and temperature employed
may
vary.
Representative solvents that may be used to prepare or recrystallize the salt
forms
include, without limitation, ethanol, methanol, propanol, 2-propanol,
isopropyl acetate, acetone,
ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone,
tert-butyl methyl
ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile.
16
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
In one embodiment the solvent is selected from ethanol, propanol, isopropyl
acetate,
water, hexane, or mixtures thereof, and the temperature used for precipitation
is between 16 C
and 25 C.
In one embodiment the acid is L-malic acid, and the solvent used is 2-
propoanol alone or
in combination with isopropyl acetate. In another embodiment the acid is
oxalic acid, and the
solvent used is aqueous 2-propanol.
In a further embodiment, the salts are (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine mono-L-malate or hemi-galactarate or oxalate
or di-p-toluoyl-
D-tartrate.
The stability of the obtained salts may be demonstrated in a variety of ways.
Propensity
to gain and release atmospheric moisture may be assessed by dynamic vapor
sorption (DVS).
Methods of Treatment
(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, or
pharmaceutically acceptable salts thereof, or a pharmaceutical composition
comprising said
compounds may be used for the prevention or treatment of various conditions or
disorders for
which other types of nicotinic compounds have been proposed or are shown to be
useful as
therapeutics, such as CNS disorders, inflammation, inflammatory response
associated with
bacterial and/or viral infection, pain, metabolic syndrome, autoimmune
disorders or other
disorders described in further detail herein. The compounds may also be used
as a diagnostic
agent in receptor binding studies (in vitro and in vivo). Such therapeutic and
other teachings are
described, for example, in references previously listed herein, including
Williams et al., Drug
News Perspec. 7(4): 205 (1994), Arneric et al., CNS Drug Rev. 1(1): 1-26
(1995), Arneric et al.,
Exp. Opin. Invest. Drugs 5(1): 79-100 (1996), Bencherif et al., J. Pharmacol.
Exp. Ther. 279:
1413 (1996), Lippiello et al., J. Pharmacol. Exp. Ther. 279: 1422 (1996),
Damaj et al., J.
Pharmacol. Exp. Ther. 291: 390 (1999); Chiari et al., Anesthesiology 91: 1447
(1999),
Lavand'homme and Eisenbach, Anesthesiology 91: 1455 (1999), Holladay et al.,
J. Med. Chem.
40(28): 4169-94 (1997), Bannon et al., Science 279: 77 (1998), PCT WO
94/08992, PCT WO
96/31475, PCT WO 96/40682, and U.S. Patent Nos. 5,583,140 to Bencherif et al.,
5,597,919 to
Dull et al., 5,604,231 to Smith et al. and 5,852,041 to Cosford et al.
One embodiment of the present invention relates to use of (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable
salt thereof in the
manufacture of a medicament.
Another embodiment of the present invention relates to use of (R)-3-((E)-2-
(pyrrolidin-3-
17
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine mono-L-malate or hemi-
galactarate or oxalate or di-
p-toluoyl-D-tartrate for use as a medicament.
One embodiment of the present invention relates to a method for the treatment
or
prevention of central nervous system (CNS) disorders, comprising administering
to a mammal in
need of such treatment, a therapeutically effective amount of (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-
5-(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt
thereof or the mono-L-
malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate. More
specifically, the disorder
may be selected from the group consisting of CNS disorders, inflammation,
inflammatory
response associated with bacterial and/or viral infection, pain, metabolic
syndrome, autoimmune
disorders or other disorders described in further detail herein.
One embodiment of the present invention relates to a pharmaceutical
composition
comprising a therapeutically effective amount of (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt
thereof or the mono-L-
malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof
and one or more
pharmaceutically acceptable carrier, diluents, excipients, or adjuvant.
One embodiment of the present invention relates to the use of a pharmaceutical
composition of the present invention in the manufacture of a medicament for
treatment of CNS
disorders.
Another embodiment of the present invention relates to use of (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable
salt thereof, or the
mono-L-malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate salt
thereof, in the
manufacture of a medicament for treatment or prevention of disorders mediated
by NNR.
Another embodiment of the present invention relates to a method of modulating
NNR in
a subject in need thereof through the administration of (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a pharmaceutically acceptable salt
thereof or the mono-L-
malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof.
CNS Disorders
((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, or
a
pharmaceutically acceptable salt thereof, or the mono-L-malate or hemi-
galactarate or oxalate
or di-p-toluoyl-D-tartrate salt thereof, or a pharmaceutical composition
comprising said
compounds are useful in the treatment or prevention of a variety of CNS
disorders, including
neurodegenerative disorders, neuropsychiatric disorders, neurologic disorders,
and addictions.
The compounds and their pharmaceutical compositions may be used to treat or
prevent
18
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
cognitive deficits and dysfunctions, age-related and otherwise; attentional
disorders and
dementias, including those due to infectious agents or metabolic disturbances;
to provide
neuroprotection; to treat convulsions and multiple cerebral infarcts; to treat
mood disorders,
compulsions and addictive behaviors; to provide analgesia; to control
inflammation, such as
mediated by cytokines and nuclear factor kappa B; to treat inflammatory
disorders; to provide
pain relief; and to treat infections, as anti-infectious agents for treating
bacterial, fungal, and viral
infections. Among the disorders, diseases and conditions that the compounds
and
pharmaceutical compositions of the present invention may be used to treat or
prevent are: age-
associated memory impairment (AAMI), mild cognitive impairment (MCI), age-
related cognitive
decline (ARCD), pre-senile dementia, early onset Alzheimer's disease, senile
dementia,
dementia of the Alzheimer's type, Alzheimer's disease, cognitive impairment no
dementia
(CIND), Lewy body dementia, HIV-dementia, AIDS dementia complex, vascular
dementia,
Down syndrome, head trauma, traumatic brain injury (TBI), dementia
pugilistica, Creutzfeld-
Jacob Disease and prion diseases, stroke, ischemia, attention deficit
disorder, attention deficit
hyperactivity disorder, dyslexia, schizophrenia, schizophreniform disorder,
schizoaffective
disorder, cognitive dysfunction in schizophrenia, cognitive deficits in
schizophrenia,
Parkinsonism including Parkinson's disease, postencephalitic parkinsonism,
parkinsonism-
dementia of Gaum, frontotemporal dementia Parkinson's Type (FTDP), Pick's
disease,
Niemann-Pick's Disease, Huntington's Disease, Huntington's chorea, tardive
dyskinesia,
hyperkinesia, progressive supranuclear palsy, progressive supranuclear
paresis, restless leg
syndrome, Creutzfeld-Jakob disease, multiple sclerosis, amyotrophic lateral
sclerosis (ALS),
motor neuron diseases (MND), multiple system atrophy (MSA), corticobasal
degeneration,
Guillain-Barre Syndrome (GBS), and chronic inflammatory demyelinating
polyneuropathy
(CIDP), epilepsy, autosomal dominant nocturnal frontal lobe epilepsy, mania,
anxiety,
depression, premenstrual dysphoria, panic disorders, bulimia, anorexia,
narcolepsy, excessive
daytime sleepiness, bipolar disorders, generalized anxiety disorder, obsessive
compulsive
disorder, rage outbursts, oppositional defiant disorder, Tourette's syndrome,
autism, drug and
alcohol addiction, tobacco addiction, and eating disorders.
Cognitive impairments or dysfunctions may be associated with psychiatric
disorders or
conditions, such as schizophrenia and other psychotic disorders, including but
not limited to
psychotic disorder, schizophreniform disorder, schizoaffective disorder,
delusional disorder,
brief psychotic disorder, shared psychotic disorder, and psychotic disorders
due to a general
medical conditions, dementias and other cognitive disorders, including but not
limited to mild
19
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
cognitive impairment, pre-senile dementia, Alzheimer's disease, senile
dementia, dementia of
the Alzheimer's type, age-related memory impairment, Lewy body dementia,
vascular dementia,
AIDS dementia complex, dyslexia, Parkinsonism including Parkinson's disease,
cognitive
impairment and dementia of Parkinson's Disease, cognitive impairment of
multiple sclerosis,
cognitive impairment caused by traumatic brain injury, dementias due to other
general medical
conditions, anxiety disorders, including but not limited to panic disorder
without agoraphobia,
panic disorder with agoraphobia, agoraphobia without history of panic
disorder, specific phobia,
social phobia, obsessive-compulsive disorder, post-traumatic stress disorder,
acute stress
disorder, generalized anxiety disorder and generalized anxiety disorder due to
a general
medical condition, mood disorders, including but not limited to major
depressive disorder,
dysthymic disorder, bipolar depression, bipolar mania, bipolar I disorder,
depression associated
with manic, depressive or mixed episodes, bipolar II disorder, cyclothymic
disorder, and mood
disorders due to general medical conditions, sleep disorders, including but
not limited to
dyssomnia disorders, primary insomnia, primary hypersomnia, narcolepsy,
parasomnia
disorders, nightmare disorder, sleep terror disorder and sleepwalking
disorder, mental
retardation, learning disorders, motor skills disorders, communication
disorders, pervasive
developmental disorders, attention-deficit and disruptive behavior disorders,
attention deficit
disorder, attention deficit hyperactivity disorder, feeding and eating
disorders of infancy,
childhood, or adults, tic disorders, elimination disorders, substance-related
disorders, including
but not limited to substance dependence, substance abuse, substance
intoxication, substance
withdrawal, alcohol-related disorders, amphetamine or amphetamine-like-related
disorders,
caffeine-related disorders, cannabis-related disorders, cocaine-related
disorders, hallucinogen-
related disorders, inhalant-related disorders, nicotine-related disorders,
opioid-related disorders,
phencyclidine or phencyclidine-like-related disorders, and sedative-, hypnotic-
or anxiolytic-
related disorders, personality disorders, including but not limited to
obsessive-compulsive
personality disorder and impulse-control disorders.
The above conditions and disorders are discussed in further detail, for
example, in the
American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders, Fourth
Edition, Text Revision, Washington, DC, American Psychiatric Association,
2000. This Manual
may also be referred to for greater detail on the symptoms and diagnostic
features associated
with substance use, abuse, and dependence.
One embodiment relates to a method of treating or preventing CNS disorders in
a
subject in need thereof comprising administering to said subject ((R)-3-((E)-2-
(pyrrolidin-3-
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, or a pharmaceutically
acceptable salt thereof, or
the mono-L-malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate
salt thereof, or a
pharmaceutical composition comprising said compounds.
In another embodiment the CNS disorders are selected from cognitive
dysfunction in
schizophrenia (CDS), Alzheimers Disease (AD), attention deficit disorder
(ADD), pre-senile
dementia (early onset of Alzheimer's Disease), dementia of the Alzheimer's
type, mild cognitive
impairment, age associated memory impairment and attention deficit
hyperactivity disorder
(ADHD). In one embodiment the CNS disorders are selected from memory
improvement and
learning improvement.
Inflammation
The nervous system, primarily through the vagus nerve, is known to regulate
the
magnitude of the innate immune response by inhibiting the release of
macrophage tumor
necrosis factor (TNF). This physiological mechanism is known as the
"cholinergic anti-
inflammatory pathway" (see, for example, Tracey, "The inflammatory reflex,"
Nature 420: 853-9
(2002)). Excessive inflammation and tumor necrosis factor synthesis cause
morbidity and even
mortality in a variety of diseases. These diseases include, but are not
limited to, endotoxemia,
rheumatoid arthritis, osteoarthritis, psoriasis, asthma, atherosclerosis,
idiopathic pulmonary
fibrosis, and inflammatory bowel disease.
Inflammatory conditions that may be treated or prevented by administering the
compounds described herein include, but are not limited to, chronic and acute
inflammation,
psoriasis, endotoxemia, gout, acute pseudogout, acute gouty arthritis,
arthritis, rheumatoid
arthritis, osteoarthritis, allograft rejection, chronic transplant rejection,
asthma, atherosclerosis,
mononuclear-phagocyte dependent lung injury, idiopathic pulmonary fibrosis,
atopic dermatitis,
chronic obstructive pulmonary disease, adult respiratory distress syndrome,
acute chest
syndrome in sickle cell disease, inflammatory bowel disease, Crohn's disease,
ulcerative colitis,
acute cholangitis, aphteous stomatitis, pouchitis, glomerulonephritis, lupus
nephritis,
thrombosis, and graft vs. host reaction.
Inflammatory Response Associated with Bacterial and/or Viral Infection
Many bacterial and/or viral infections are associated with side effects
brought on by the
formation of toxins, and the body's natural response to the bacteria or virus
and/or the toxins. As
discussed above, the body's response to infection often involves generating a
significant
amount of TNF and/or other cytokines. The over-expression of these cytokines
can result in
21
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
significant injury, such as septic shock (when the bacteria is sepsis),
endotoxic shock,
urosepsis, viral pneumonitis, and toxic shock syndrome.
Cytokine expression is mediated by NNRs, and may be inhibited by administering
agonists or partial agonists of these receptors. Those compounds described
herein that are
agonists or partial agonists of these receptors may therefore be used to
minimize the
inflammatory response associated with bacterial infection, as well as viral
and fungal infections.
Examples of such bacterial infections include anthrax, botulism, and sepsis.
Some of these
compounds may also have antimicrobial properties.
The compounds of the present invention may also be used as adjunct therapy in
combination with existing therapies to manage bacterial, viral and fungal
infections, such as
antibiotics, antivirals and antifungals. Antitoxins may also be used to bind
to toxins produced by
the infectious agents and allow the bound toxins to pass through the body
without generating an
inflammatory response. Examples of antitoxins are disclosed, for example, in
U.S. Patent No.
6,310,043 to Bundle et al. Other agents effective against bacterial and other
toxins may be
effective and their therapeutic effect may be complemented by co-
administration with the
compounds described herein.
Pain
The compounds may be administered to treat and/or prevent pain, including
acute,
neurologic, inflammatory, neuropathic and chronic pain. The analgesic activity
of compounds
described herein may be demonstrated in models of persistent inflammatory pain
and of
neuropathic pain, performed as described in U.S. Published Patent Application
No.
20010056084 Al (Allgeier et al.) (e.g., mechanical hyperalgesia in the
complete Freund's
adjuvant rat model of inflammatory pain and mechanical hyperalgesia in the
mouse partial
sciatic nerve ligation model of neuropathic pain).
The analgesic effect is suitable for treating pain of various genesis or
etiology, in
particular in treating inflammatory pain and associated hyperalgesia,
neuropathic pain and
associated hyperalgesia, chronic pain (e.g., severe chronic pain, post-
operative pain and pain
associated with various conditions including cancer, angina, renal or biliary
colic, menstruation,
migraine and gout). Inflammatory pain may be of diverse genesis, including
arthritis and
rheumatoid disease, teno-synovitis and vasculitis. Neuropathic pain includes
trigeminal or
herpetic neuralgia, neuropathies, diabetic neuropathy pain, causalgia, low
back pain and
deafferentation syndromes such as brachial plexus avulsion.
22
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
One embodiment relates to a method of treating pain in a subject in need
thereof
comprising administering to said subject ((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-
5-(tetrahydropyran-
4-yloxy)pyridine, or a pharmaceutically acceptable salt thereof, or the mono-L-
malate or hemi-
galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof, or a
pharmaceutical composition
comprising said compounds.
Other Disorders
In addition to treating CNS disorders, inflammation, and pain, the compounds
of the
present invention may be also used to prevent or treat certain other
conditions, diseases, and
disorders in which NNRs play a role. Examples include autoimmune disorders
such as lupus,
disorders associated with cytokine release, cachexia secondary to infection
(e.g., as occurs in
AIDS, AIDS related complex and neoplasia), obesity, pemphitis, urinary
incontinence, retinal
diseases, infectious diseases, myasthenia, Eaton-Lambert syndrome, dystonia,
hypertension,
osteoporosis, vasoconstriction, vasodilatation, cardiac arrhythmias, type I
diabetes, type II
diabetes, ulcers, bulimia, anorexia, constipation, and diarrhea, as well as
those indications set
forth in published PCT application WO 98/25619. The compounds of this
invention may also be
administered to treat convulsions such as those that are symptomatic of
epilepsy, and to treat
conditions such as syphillis and Creutzfeld-Jakob disease.
Diagnostic Uses
Another embodiment of the present invention relates to compounds that have
utility as
diagnostic agents and in receptor binding studies as described herein.
The compounds may be used in diagnostic compositions, such as probes,
particularly
when they are modified to include appropriate labels. The probes may be used,
for example, to
determine the relative number and/or function of specific receptors,
particularly the a4132
receptor subtype. For this purpose the compounds of the present invention most
preferably are
labeled with a radioactive isotopic moiety such as 11C, 18F, 76Br,1231 or
1251.
One embodiment of the invention relates to ((R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine, or a pharmaceutically acceptable salt
thereof, or the mono-L-
malate or hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof,
wherein one to three
of the atoms represents a detectable isotope selected from 3H, 19F and 13C, or
wherein one of
the atoms is a detectable isotope selected from 18F, 11C and 14C.
The administered compounds may be detected using known detection methods
appropriate for the label used. Examples of detection methods are
scintillation counting,
position emission topography (PET), single-photon emission computed tomography
(SPECT),
23
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
gamma imaging, magnetic resonance imaging (MRI) or magnetic resonance
spectroscopy
(MRS). The radiolabels described above are useful in PET (e.g., "C, 18F or
76Br) and SPECT
(e.g., 1231) imaging, with half-lives of about 20.4 min for 11C, about 109 min
for 18F, about 13 h
for 1231, and about 16 h for 76Br. A high specific activity is desired to
visualize the selected
receptor subtypes at non-saturating concentrations. The administered doses
typically are low
and provide high contrast images. Determination of dose is carried out in a
manner known to
one skilled in the art of radiolabel imaging. The compounds may be
administered in
compositions that incorporate other ingredients, such as those types of
ingredients that are
useful in formulating a diagnostic composition. Compounds useful in accordance
with carrying
out the present invention most preferably are employed in forms of high
purity. After the
compounds are administered to a subject (e.g., a human subject), the presence
of that
compound within the subject may be imaged and quantified by appropriate
techniques in order
to indicate the presence, quantity, and functionality of selected NNR
subtypes. In addition to
humans, the compounds may also be administered to animals, such as mice, rats,
horses,
dogs, and monkeys. SPECT and PET imaging may be carried out using any
appropriate
technique and apparatus. The radiolabeled compounds bind with high affinity to
selective NNR
subtypes (e.g., a4132) and preferably exhibit negligible non-specific binding
to other nicotinic
cholinergic receptor subtypes (e.g., those receptor subtypes associated with
muscle and
ganglia). As such, the compounds may be used as agents for noninvasive imaging
of nicotinic
cholinergic receptor subtypes within the body of a subject, particularly
within the brain for
diagnosis associated with a variety of CNS diseases and disorders.
In one aspect, the diagnostic compositions may be used in a method to diagnose
disease in a subject, such as a human patient. The method involves
administering to that
patient a detectably labeled compound as described herein, and detecting the
binding of that
compound to selected NNR subtypes (e.g., a4R2 receptor subtypes). Those
skilled in the art of
using diagnostic tools, such as PET and SPECT, can use the radiolabeled
compounds
described herein to diagnose a wide variety of conditions and disorders,
including conditions
and disorders associated with dysfunction of the central and autonomic nervous
systems. Such
disorders include a wide variety of CNS diseases and disorders, such as
Alzheimer's disease,
Parkinson's disease, and schizophrenia or any disorder herein mentioned.
Receptor Binding
The compounds of this invention may be used as reference ligands in binding
assays for
compounds which bind to NNR subtypes, particularly the a4132 receptor
subtypes. For this purpose
24
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
the compounds of this invention are preferably labeled with a radioactive
isotopic moiety such as 3H,
or 14C. Examples of such binding assays are described in detail below.
Pharmaceutical Compositions
In one aspect the present invention relates to pharmaceutical compositions
comprising the
compound of the present invention and one or more pharmaceutically acceptable
carrier,
diluent, or excipient. Another aspect of the invention provides a process for
the preparation of
a pharmaceutical composition including admixing the compound of the present
invention with
one or more pharmaceutically acceptable carrier, diluent, or excipient.
The manner in which the compound of the present invention is administered may
vary.
The compound of the present invention is preferably administered orally.
Preferred
pharmaceutical compositions for oral administration include tablets, capsules,
caplets, syrups,
solutions, and suspensions. The pharmaceutical compositions of the present
invention may be
provided in modified release dosage forms such as time-release tablet and
capsule
formulations.
The pharmaceutical compositions may also be administered via injection,
namely,
intravenously, intramuscularly, subcutaneously, intraperitoneally,
intraarterially, intrathecally, and
intracerebroventricularly. Carriers for injection may include 5% dextrose
solutions, saline, and
phosphate buffered saline.
The compositions may also be administered using other means, for example,
rectal
administration. The compounds may also be administered by inhalation, for
example, in the
form of an aerosol; topically, such as, in lotion form; transdermally, such
as, using a transdermal
patch (for example, by using technology that is commercially available from
Novartis and Alza
Corporation), by powder injection, or by buccal, sublingual, or intranasal
absorption.
Pharmaceutical compositions may be formulated in unit dose form, or in
multiple or
subunit doses forms.
The administration of the pharmaceutical compositions described herein may be
intermittent, or at a gradual, continuous, constant or controlled rate. The
pharmaceutical
compositions may be administered to a warm-blooded animal, for example, a
mammal such as
a mouse, rat, cat, guinea pig, rabbit, horses, dog, pig, cow, or monkey; but
advantageously is
administered to a human being.
Combinations
The compound of the present invention may be used in the treatment of a
variety of
disorders and conditions and, as such, may be used in combination with a
variety of other
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
therapeutic agents useful in the treatment or prophylaxis of those disorders.
Thus, one
embodiment of the present invention relates to the administration of the
compound of the
present invention in combination with other therapeutic agents. For example,
the compound of
the present invention may be used in combination with other NNR ligands (such
as varenicline),
antioxidants (such as free radical scavenging agents), antibacterial agents
(such as penicillin
antibiotics), antiviral agents (such as nucleoside analogs, like zidovudine
and acyclovir),
anticoagulants (such as warfarin), anti-inflammatory agents (such as NSAIDs),
anti-pyretics,
analgesics, anesthetics (such as used in surgery), acetylcholinesterase
inhibitors (such as
donepezil and galantamine), antipsychotics (such as haloperidol, clozapine,
olanzapine, and
quetiapine), immuno-suppressants (such as cyclosporin and methotrexate),
neuroprotective
agents, steroids (such as steroid hormones), corticosteroids (such as
dexamethasone,
predisone, and hydrocortisone), vitamins, minerals, nutraceuticals, anti-
depressants (such as
imipramine, fluoxetine, paroxetine, escitalopram, sertraline, venlafaxine, and
duloxetine),
anxiolytics (such as alprazolam and buspirone), anticonvulsants (such as
phenytoin and
gabapentin), vasodilators (such as prazosin and sildenafil), mood stabilizers
(such as vaiproate
and aripiprazole), anti-cancer drugs (such as anti-proliferatives), anti
hypertensive agents (such
as atenolol, clonidine, amlopidine, verapamil, and olmesartan), laxatives,
stool softeners,
diuretics (such as furosemide), anti-spasmotics (such as dicyclomine), anti-
dyskinetic agents,
and anti-ulcer medications (such as esomeprazole). Such a combination of
therapeutic agents
may be administered together or separately and, when administered separately,
administration
may occur simultaneously or sequentially, in any order. The amounts of the
compounds or
agents and the relative timings of administration will be selected in order to
achieve the
desired therapeutic effect. The administration in combination of a compound of
the present
invention with other therapeutic agents may be in combination by
administration concomitantly
in: (1) a unitary pharmaceutical composition including both compounds; or (2)
separate
pharmaceutical compositions each including one of the compounds.
Alternatively, the
combination may be administered separately in a sequential manner wherein one
treatment
agent is administered first and the other second. Such sequential
administration may be
close in time or remote in time.
Another aspect of the present invention relates to combination therapy
comprising
administering to the subject a therapeutically or prophylactically effective
amount of the
compound of the present invention and one or more other therapeutic agents
including
chemotherapeutics, radiation therapuetic agents, gene therapeutic agents, or
agents used in
26
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
immunotherapy.
Low dose
((R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof is
a substrate for Pgp brain pump which is located in the blood brain barrier.
The Pgp pump is
responsible for pumping substances out of the brain. Due to this pump, it is
often difficult to get
drugs into the brain in therapeutically effective amounts. This often results
in the administration
of high doses of drugs, which at these high levels may have side effects in
other parts of the
human body.
((R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropy ran-4-yloxy)pyridine,
although being a
substrate for the PGP pump, can be administered at low doses while at the same
time have a
relatively long duration of effect. For example, compared to acetylcholine,
the natural agonist
for NNR, the response for ((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine
is twice as great in the in vitro assay at a402.
One embodiment of the invention relates to administration of a pharmaceutical
composition comprising ((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropy
ran-4-yloxy)py ridine,
or a pharmaceutically acceptable salt thereof, in certain embodiments, the
mono-L-malate or
hemi-galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof, in
amounts of between 1 to
2200 pg/day. In another embodiment the amount is 50 to 1500 pg/day. In a
further
embodiment the amount is 50 to 1000 pg/day. In one embodiment the amount is 50
to 500
pg/day. In another embodiment the amount is 75 to 300 pg/day. In yet another
embodiment the
amount is 75 to 200 pg/day. In yet a further embodiment the amount is 75 to
150 pg/day.
The dose of ((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine, or a
pharmaceutically acceptable salt thereof, oin certain embodiments, the mono-L-
malate or hemi-
galactarate or oxalate or di-p-toluoyl-D-tartrate salt thereof, may be
administered one, two, or
three times daily. One embodiment relates to once daily administration.
Another embodiment
relates to twice daily administration.
Another embodiment of the invention relates to a NNR agonist which has a half
life (t,)
between 5 and 8 hours. In one embodiment the t,, is between 6 and 7 hours. In
another
embodiment the t y, is 6.8 hours.
Another embodiment of the invention relates to a NNR agonist which has a
duration of
action between 5 and 10 hours. In one embodiment the duration is between 6 to
9 hours. In a
further embodiment the duration is 8 hours.
In a further embodiment the agonist is an a4(32 agonist.
27
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
In yet another embodiment the agonist is ((R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-
5-
(tetrahydropyran-4-yloxy)pyridine.
Examples
The following examples are provided to illustrate the present invention, and
should not be
construed as limiting thereof. In these examples, all parts and percentages
are by weight, unless
otherwise noted.
Example 1: Instrumentation and experimental protocols for characterization of
(R)-3-((E)-
2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine and its salt
forms
Nuclear Magnetic Resonance (NMR) Spectrometry
NMR spectra were collected on either a Varian Unity 300 MHz instrument or a
Bruker
400MHz instrument equipped with an auto-sampler and controlled by a DRX400
console.
Automated experiments were acquired using ICONNMR v4Ø4 (build 1) running
with Topspin v
1.3 (patch level 8) using the standard Bruker loaded experiments. For non-
routine spectroscopy,
data were acquired through the use of Topspin alone.
Melting Point
A Fisher-Johns hot stage melting point apparatus was used, at a setting
corresponding
to a heating rate of about 5 C per min.
Differential Scanning Calorimetry (DSC)
DSC data were collected on a TA Instruments Q1000 or a Mettler DSC 823e
equipped
with a 50 position auto-sampler. The instrument was calibrated for energy and
temperature
calibration using certified indium. Typically 0.5-1.5 mg of each sample, in a
pin-holed aluminium
pan, was heated at 10 C/min from 25 C to 175-200 C. A nitrogen purge at 30
mL/min was
maintained over the sample.
Dynamic Vapor Sorption (DVS)
Sorption isotherms were determined using a SMS DVS Intrinsic moisture sorption
analyzer controlled by SMS Analysis suite software. The sample temperature was
maintained
at 25 C by the instrument controls. The humidity was controlled by mixing
streams of dry and
wet nitrogen, with a total flow rate of 200 mL/min. The relative humidity was
measured by a
calibrated Rotronic probe (dynamic range of 1.0-100 %RH), located near the
sample. The
weight change, (mass relaxation) of the sample as a function of %RH was
constantly monitored
by the microbalance (accuracy 0.005 mg).
28
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Typically a 5-20 mg sample was placed on the tared mesh stainless steel basket
under
ambient conditions. The sample was loaded and unloaded at 40% RH and 25 C
(typical
ambient conditions). A moisture sorption isotherm was performed as outlined
below (2 scans
giving 1 complete cycle). The standard isotherm was performed at 25 C at 10%
RH intervals
over a 0-90% RH range.
DVS Generic method parameters
Parameters Values
Adsorption - Scan 1 40 - 90
Desorption / Adsorption - Scan 2 90 - Dry, Dry - 40
Intervals (% RH) 10
Number of Scans 2
Flow rate mL/min 200
Temperature (*C) 25
Stability C/min 0.2
Sorption Time h 6 hour time out
Chemical Purity by HPLC
Purity analysis was performed on an Agilent HP1 100 series system equipped
with a
diode array detector and using ChemStation software vB.02.01-SR1.
HPLC method parameters for chemical purity determination:
-Sample Preparation 0.5 m /mL in acetonitrile:water 1:1 (v/v)
Column: Phenomenex Luna C18 (2), 150 x 4.6 mm, 5 pm
Column Temperature (OC): 25
Injection L : 5
Detection: 255,90
Wavelength, Bandwidth( nm :
Flow Rate mUmin : 1
Phase A: 0.1 % TFA in water
Phase B: 0.085% TFA in acetonitrile
Timetable: Time min % Phase A % Phase B
0 95 5
25 5 95
25.2 95 5
30 95 5
Ion Chromatography
Data were collected on a Metrohm 761 Advanced Compact IC (for cations) and a
Metrohm 861 Advanced Compact IC (for anions) using IC Net software v2.3.
Samples were
prepared as 1000 ppm stocks in DMSO. Samples were diluted to 100 ppm with DMSO
prior to
29
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
testing. Quantification was achieved by comparison with standard solutions of
known
concentration of the ion being analyzed.
Ion Chromatography method for anions:
Type of method Anion exchange
Column: Metrosep A Supp 5 - 250 (4.0 x 250 mm)
Column Temperature ('C): Ambient
Injection L): 20
Detection: Conductivity detector
Flow Rate mUmin : 0.7
Eluent: 3.2 mM sodium carbonate,
1.0 mM sodium hydrogen carbonate in water
Ion Chromatography method for cations:
Type of method Cation exchange
Column: Metrosep C 2 - 250 (4.0 x 250 mm)
Column Temperature ( C): Ambient
Injection L : 20
Detection: Conductivity detector
Flow Rate mL/min : 1.0
Eluent: 4.0 mM Tartaric acid,
0.75 mM Dipicolinic acid in water
Example 2. Synthesis of tert-butyl (R)-3-(methylsulfonyloxy)pyrrolidine-1-
carboxylate (2)
Procedure A: To a solution of tert-butyl (R)-3-hydroxypyrrolidine-1-
carboxylate (200 g,
1.07 mol) and triethylamine (167 g, 1.63 mol) in toluene (700 mL) at -20 to -
30 C was added
methanesulfonyl chloride (156 g, 1.36 mol) drop-wise while maintaining the
temperature at -10
to -20 C. The solution was warmed to ambient temperature and allowed to stir.
The reaction
solution was sampled hourly and analyzed by HPLC to establish completion of
the reaction.
Upon completion of the reaction, the suspension was filtered to remove the
triethylamine
hydrochloride. The filtrate was washed with -600 mL of dilute aqueous sodium
bicarbonate
solution. The organic layer was dried and concentrated under reduced pressure
to give 2 as a
viscous oil (260 g, 92%) which is used without further purification. 1H NMR
(CDC13, 400 MHz) b
5.27 (m, 1 H), 3.44 - 3.76 (m, 4H), 3.05 (s, 3H), 2.26 (m, 1 H), 2.15 (m, 1
H), 1.47 (s, 9H).
Procedure B: A reactor was charged with tert-butyl (R)-3-hydroxypyrrolidine-1 -
carboxylate (2.00 kg, 10.7 mol), toluene (8.70 kg) and triethylamine (1.75 kg,
17.3 mol). The
reactor was flushed with nitrogen for 15 min. The mixture was stirred and
cooled to 3 C.
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Methanesulfonyl chloride (1.72 kg, mol) was slowly added (over a 2 h period)
with continuous
ice bath cooling (exothermic reaction) (after complete addition, the
temperature was 14 C).
The mixture, now viscous with precipitated triethylamine hydrochloride, was
stirred 12 h as it
warmed to 20 C. Both GC and TLC analysis (ninhydrin stain) indicated that no
starting material
remained. The mixture was filtered to remove the triethylamine hydrochloride,
and the filtrate
was returned to the reactor. The filtrate was then washed (2 x 3 kg) with 5%
aqueous sodium
bicarbonate, using 15 min of stirring and 15 min of settling time for each
wash. The resulting
organic layer was dried over anhydrous sodium sulfate and filtered. The
volatiles were removed
from the filtrate under vacuum, first at 50 C for 4 h and then at ambient
temperature for 10 h.
The residue weighed 3.00 kg (106% yield) and was identical by chromatographic
and NMR
analysis to previously prepared samples, with the exception that it contained
toluene.
Example 3. Synthesis of diethyl (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-
yl)malonate (3)
Preparation A: To a solution of potassium tert-butoxide (187 g, 1.62 mol) in 1-
methyl-2-
pyrrolidinone (1.19 L) was added diethyl malonate (268 g. 1.67 mol) while
maintaining the
temperature below 35 C. The solution was heated to 40 C and stirred for 20-
30 min. tert-
Butyl (R)-3-(methylsulfonyloxyl)pyrrolidine-1-carboxylate (112 g, 420 mmol)
was added and the
solution was heated to 65 C and stirred for 6 h . The reaction solution was
sampled every 2 h
and analyzed by HPLC to establish completion of the reaction. Upon completion
of reaction
(10-12 h ),the mixture was cooled to around 25 C. De-ionized water (250 mL)
was added to
the solution, and the pH was adjusted to 3-4 by addition of 2N hydrochloric
acid (650 mL). The
resulting suspension was filtered, and water (1.2 L) and chloroform (1.4 L)
were added. The
solution was mixed thoroughly, and the chloroform layer was collected and
evaporated under
reduced pressure to give a yellow oil. The oil was dissolved in hexanes (2.00
L) and washed
with deionized water (2 x 1.00 L). The organic layer was concentrated under
reduced pressure
at 50-55 C to give a pale yellow oil (252 g) which 1H NMR analysis indicates
to be 49.1% of 3
(123.8 g) along with 48.5% diethyl malonate (122g), and 2% of 1-methyl-2-
pyrrolidinone (5 g).
The material was carried forward into the next step without further
purification. 1H NMR (CDC13,
400 MHz) b 4.20 (q, 4H), 3.63 (m, 1 H), 3.48 (m, 1 H), 3.30 (m, 1 H), 3.27 (d,
J = 10 Hz, 1 H), 3.03
(m, 1 H), 2.80 (m, 1 H), 2.08 (m, 1 H), 1.61 (m, 1 H), 1.45 (s, 9H), 1.27 (t,
6H).
Preparation B: A reactor, maintained under a nitrogen atmosphere, was charged
with
200 proof ethanol (5.50 kg) and 21 % (by weight) sodium ethoxide in ethanol
(7.00 kg, 21.6 mol).
The mixture was stirred and warmed to 30 C. Diethyl malonate (3.50 kg, 21.9
mol) was added
over a 20 min period. The reaction mixture was then warmed at 40 C for 1.5 h.
A solution of
31
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
tert-butyl (R)-3-(methylsulfonyloxyl)pyrrolidine-1-carboxylate (3.00 kg of the
product from
Example 2, Procedure B, 10.7 mol) in 200 proof ethanol (5.50 kg) was added,
and the resulting
mixture was heated at reflux (78 C) for 2 h. Both GC and TLC analysis
(ninhydrin stain)
indicated that no starting material remained. The stirred mixture was then
cooled to 25 C,
diluted with water (2.25 kg), and treated slowly with a solution of
concentrated hydrochloric acid
(1.27 kg, 12.9 mol) in water (5.44 kg). This mixture was washed twice with
methyl tert-butyl
ether (MTBE) (14.1 kg and 11.4 kg), using 15 min of stirring and 15 min of
settling time for each
wash. The combined MTBE washes were dried over anhydrous sodium sulfate (1
kg), filtered
and concentrated under vacuum at 50 C for 6 h. The residue (red oil) weighed
4.45 kg and
was 49% desired product by GC analysis (62% overall yield from tert-butyl (R)-
3-
hydroxypyrrolidine-1 -carboxylate).
Example 4. Synthesis of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonic
acid (4)
Procedure A: To a solution of the product of Example 3, Procedure A (232 g),
containing 123.8 g (380 mmol) of 3 and 121.8 g (760 mmol) of diethyl malonate,
in
tetrahydrofuran (1.2 L) was added a 21% potassium hydroxide solution (450 g in
0.50 L of
deionized water) while maintaining the temperature below 25 C. The reaction
mixture was
heated to 45 C and stirred for 1 h. The reaction solution was sampled every
hour and analyzed
by HPLC to establish completion of the reaction. Upon completion of reaction
(2-3 h), the
mixture was cooled to around 25 C. The aqueous layer was collected and cooled
to 5 C. The
pH was adjusted to 2 by addition of 4N hydrochloric acid (750 mL), and the
resulting suspension
was held at 5 - 10 C for 30 min. The mixture was filtered, and the filter
cake was washed with
hexanes (1 L). The aqueous filtrate was extracted with chloroform (1 L) and
the chloroform
layer was put aside. The solids collected in the filtration step were re-
dissolved in chloroform (1
L) by heating to 40 C. The solution was filtered to remove un-dissolved
inorganic solids. The
chloroform layers were combined and concentrated under reduced pressure at 50 -
55 C to
give an off-white solid (15 g). The solids were combined and dissolved in
ethyl acetate (350
mL) to give a suspension that was warmed to 55 - 60 C for 2h. The suspension
was filtered
while hot and the resulting cake washed with ethyl acetate (2 x 150 ml-) and
hexanes (2 x 250
ml-) to give 83.0 g (80.1 %) of 4 as a white solid which was used in the next
step without further
purification. 1 H NMR (d4-CH3OH, 400 MHz) 6 3.60 (m, 1 H), 3.46 (m, 1 H), 3.29-
3.32 (m, 2H),
2.72 (m, 1 H), 2.09 (m, 1 H), 1.70 (m, 1 H), 1.45 (s, 9H).
Procedure B: A solution of the product of Example 3, Procedure B (4.35 kg),
containing
2.13 kg (6.47 mol) of 3, in tetrahydrofuran (13.9 kg) was added to a stirred,
cooled solution of
32
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
potassium hydroxide (1.60 kg, 40.0 mol) in deionized water (2.00 kg) under a
nitrogen
atmosphere, while maintaining the temperature below 35 C. The reaction
mixture was heated
and maintained at 40 - 45 C for 24 h, by which time GC and TLC analysis
indicated that the
reaction was complete. The mixture was cooled to 25 C and washed with MTBE
(34 kg), using
15 min of stirring and 15 min of settling time. The aqueous layer was
collected and cooled to 1
C. A mixture of concentrated hydrochloric acid (2.61 kg, 26.5 mol) in
deionized water (2.18 kg)
was then added slowly, keeping the temperature of the mixture at <15 C during
and for 15 min
after the addition. The pH of the solution was adjusted to 3.7 by further
addition of hydrochloric
acid. The white solid was collected by filtration, washed with water (16 kg),
and vacuum dried at
ambient temperature for 6 d. The dry solid weighed 1.04 kg. The filtrate was
cooled to <10 C
and kept at that temperature as the pH was lowered by addition of more
hydrochloric acid (1.6 L
of 6 N was used; 9.6 mol; final pH = 2). The white solid was collected by
filtration, washed with
water (8 L), and vacuum dried at 40 C for 3 d. The dry solid weighed 0.25 kg.
The combined
solids (1.29 kg, 73% yield) were chromatographically identical to previously
prepared samples.
Example 5. Synthesis of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidine-3-yl)acetic
acid (5)
Procedure A: A solution of (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-
yl)malonic acid (83
g) in 1-methyl-2-pyrrolidinone (0.42 L) was stirred under nitrogen at 110-112
C for 2 h . The
reaction solution was sampled every hour and analyzed by HPLC to establish
completion of the
reaction. Upon completion of reaction the reaction solution was cooled to 20-
25 C. The
solution was mixed with de-ionized water (1.00 L), and MTBE (1.00 L) was
added. The phases
were separated, and the organic layer was collected. The aqueous phase was
extracted with
MTBE (1.00 L), then chloroform (1.00 Q. The organic layers were combined and
concentrated
under reduced pressure at 50-55 C to give an oil. This oil was dissolved in
MTBE (2.00 L) and
washed twice with 0.6N hydrochloric acid (2 x 1.00 Q. The organic layer was
collected and
concentrated under reduced pressure at 50-55 C to give a semi-solid. The semi-
solid was
suspended in 1:4 ethyl acetate/hexanes (100 mL), heated to 50 C, held for 30
min, cooled to -
10 C, and filtered. The filtrate was concentrated under reduced pressure to
give an oil, which
was dissolved in MTBE (250 mL) and washed twice with 0.6N hydrochloric acid (2
x 100 mL).
The organic layer was concentrated under reduced pressure at 50-55 C to give
a semi-solid
which was suspended in 1:4 ethyl acetate/hexanes (50 mL), heated to 50 C,
held for 30 min,
cooled to -10 C, and filtered. The solids were collected, suspended in
hexanes (200 mL), and
collected by filtration to give 54.0 g (77.6%) of 5. 1H NMR (CDC13, 400 MHz) 6
11.00 (br s, 1 H),
33
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
3.63 (m, 1 H), 3.45 (M, 1 H), 3.30 (M, 1 H), 2.97 (m, 1 H), 2.58 (m, 1 H),
2.44 (m, 2H), 2.09 (m, 1 H),
1.59 (M, 1 H), 1.46 (s, 9H).
Procedure B: A solution of (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-
yl)malonic acid
(1.04 kg, 3.81 mol) in 1-methyl-2-pyrrolidinone (6.49 kg) was stirred under
nitrogen at 110 C for
5 h , by which time TLC and HPLC analysis indicated that the reaction was
complete. The
reaction mixture was cooled to 25 C (4 h) and combined with water (12.8 kg)
and MTBE (9.44
kg). The mixture was stirred vigorously for 20 min, and the phases were
allowed to separate
(10 h). The organic phase was collected, and the aqueous phase was combined
with MTBE
(9.44 kg), stirred for 15 min, and allowed to settle (45 min). The organic
phase was collected,
and the aqueous phase was combined with MTBE (9.44 kg), stirred for 15 min,
and allowed to
settle (15 min). The three organic phases were combined and washed three times
with 1 N
hydrochloric acid (8.44 kg portions) and once with water (6.39 kg), using 15
min of stirring and
min of settling time for each wash. The resulting solution was dried over
anhydrous sodium
sulfate (2.0 kg) and filtered. The filtrate was concentrated under reduced
pressure at 31 C (2
15 h) to give an solid. This solid was heated under vacuum for 4 h at 39 C
for 4 h and for 16 h at
C, leaving 704 g (81 %) of 5 (99.7% purity by GC).
Procedure C (streamlined synthesis of 5, using 2 as starting material): A
stirred mixture
of sodium ethoxide in ethanol (21 weight percent, 343 g, 1.05 mol), ethanol
(anhydrous, 300
mL) and diethyl malonate (168 g, 1.05 mol) was heated to 40 C for 1.5 h. To
this mixture was
20 added a solution of (R)-tent-butyl 3-(methylsulfonyloxy)pyrrolidine-1-
carboxylate (138 g, 0.592
mol) in ethanol (100 mL) and the reaction mixture was heated to 78 C for 8 h.
The cooled
reaction mixture was diluted with water (2.0 L) and acidified to pH = 3 with
6M HCI (100 mL).
The aqueous ethanol mixture was extracted with toluene (1.0 L), and the
organic phase
concentrated under vacuum to afford 230 g of a red oil. The red oil was added
at 85 C to a
25 22.5 weight percent aqueous potassium hydroxide (748 g, 3.01 mol). After
the addition was
complete, the reaction temperature was allowed to slowly rise to 102 C while
a distillation of
ethanol ensued. When the reaction temperature had reached 102 C, and
distillation had
subsided, heating was continued for an additional 90 min. The reaction mixture
was cooled to
ambient temperature and washed with toluene (2 x 400 mL). To the aqueous layer
was added
600 mL 6M hydrochloric acid, while keeping the internal temperature below 20
C. This resulted
in the formation of a precipitate, starting at pH of about 4-5. The suspension
was filtered, and
the filter cake was washed with 300 mL water. The solid was dried under vacuum
to afford 77 g
of (R)-2-(1-(tent-butoxycarbonyl)pyrrolidin-3-yl)malonic acid as an off-white
solid (54% yield with
34
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
respect to (R)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate). 1H
NMR (DMSO-d6,
400 MHz): 6 3.47 (m, 1 H); 3.32 (m, 1 H); 3.24 (m, 1 H); 3.16 (m, 1 H); 3.92
(m, 1 H); 2.86 (m, 1 H);
1.95 (m, 1 H); 1.59 (m, 1 H); 1.39 (s, 9H).
A suspension of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonic acid (15
g, 55 mmol) in
toluene (150 mL) and dimethylsulfoxide (2 mL) was heated to reflux for a
period of 2 h. The
mixture was allowed to reach ambient and diluted with MTBE (150 mL). The
organic solution
was washed with 10% aqueous citric acid (2 x 200 mL), and the solvent was
removed under
vacuum to afford 11.6 g of (R)-2-(1-(tert-butoxycarbonyl)-pyrrolidin-3-
yl)acetic acid as an off-
white solid (92% yield). 'H NMR (DMSO-d6, 400 MHz): b 12.1 (s, 1 H); 3.36-3.48
(m, 1 H); 3.20-
3.34 (m, 1 H); 3.05-3.19 (m, 1 H; 2.72-2.84 (m, 1 H); 2.30-2.42 (m, 1 H), 2.22-
2.30 (m, 2H); 1.85-
2.00 (m, 1 H); 1.38-1.54 (m, , 1 H), 1.35 (2, 9H).
Example 6. Synthesis of tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-
carboxylate (6)
Procedure A: A solution of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidine-3-
yl)acetic acid
(49.0 g, 214 mmol) in tetrahydrofuran (THF) (200 mL) was cooled to -10 C. 250
mL (250
mmol) of a 1 M borane in THF solution was added slowly to the flask while
maintaining the
temperature lower than 0 C. The solution was warmed to ambient temperature
and stirred for
1 h. The solution was sampled hourly and analyzed by HPLC to establish
completion of the
reaction. Upon completion of the reaction, the solution was cooled to 0 C,
and a 10% sodium
hydroxide solution (80 mL) was added drop-wise over a 30 minute period to
control gas
evolution. The solution was extracted with 500 mL of a 1:1 hexanes/ethyl
acetate solution. The
organic layer was washed with saturated sodium chloride solution and dried
with 10 g of silica
gel. The silica gel was removed by filtration and washed with 100 mL of 1:1
hexanes/ethyl
acetate. The organic layers were combined and concentrated under vacuum to
give 6 (42 g,
91.3 %) as a light-orange oil that solidified upon sitting. 'H NMR (CDC13, 400
MHz) b 3.67 (m,
2H), 3.38-3.62 (m, 2H), 3.25 (m, 1 H), 2.90 (m, 1 H), 2.25 (m, 1 H), 1.98-2.05
(m, 1 H), 1.61-1.69
(m, 2H), 1.48-1.59 (m, 2H), 1.46 (s, 9H).
Procedure B: Borane-THF complex (3.90 kg or L of 1 M in THF, mol) was added
slowly
to a stirred solution of (R)-2-(1-(tert-butoxycarbonyl)pyrrolidine-3-yl)acetic
acid (683 g, 3.03 mol)
in THF (2.5 kg), kept under nitrogen gas, and using a water bath to keep the
temperature
between 23 and 28 C. The addition took 1.75 h. Stirring at 25 C was
continued for 1 h, after
which time GC analysis indicated complete reaction. The reaction mixture was
cooled to <10 C
and maintained below 25 C as 10% aqueous sodium hydroxide (1.22 kg) was
slowly added.
The addition took 40 min. The mixture was stirred 1 h at 25 C, and then
combined with 1:1
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(v/v) heptane/ethyl acetate (7 Q. The mixture was stirred for 15 min and
allowed to separate
into phases (1 h). The organic phase was withdrawn, and the aqueous phase was
combined
with a second 7 L portion of 1:1 heptane/ethyl acetate. This was stirred for
15 min and allowed
to separate into phases (20 min). The organic phase was again withdrawn, and
the combined
organic phases were washed with saturate aqueous sodium chloride (4.16 kg),
using 15 min of
mixing and 1 h of settling time. The organic phase was combined with silica
gel (140 g) and
stirred 1 h. The anhydrous sodium sulfate (700 g) was added, and the mixture
was stirred for
1.5 h. The mixture was filtered, and the filter cake was washed with 1:1
heptane/ethyl acetate
(2 L). The filtrate was concentrated under vacuum at <40 C for 6 h. The
resulting oil weighed
670 g (103% yield) and contains traces of heptane, but is otherwise identical
to previously
prepared samples of 6, by NMR analysis.
Example 7: tert-butyl (R)-3-(2-(methylsulfonyloxy)ethyl)pyrrolidine-1-
carboxylate (7)
Procedure A: To a solution of tert-butyl (R)-3-(2-hydroxymethyl) pyrrolidine-1-
carboxylate
(41.0 g, 190 mmol)) was added triethylamine (40 mL) in toluene (380 mL) and
cooled to -10 C.
Methanesulfonyl chloride (20.0 mL, 256 mmol) was added slowly so as to
maintain the
temperature around -5 to 0 C. The solution was warmed to ambient temperature
and stirred for
1 In. The solution was sampled hourly and analyzed by HPLC to establish
completion of the
reaction. Upon completion of reaction, the solution was filtered, and the
filtrate was washed
with a 5% sodium bicarbonate solution (250 mL). The organic layer was
collected and washed
with a saturated aqueous sodium chloride solution (250 mL). The organic layer
was collected,
dried over silica gel (10 g), and concentrated under vacuum to give 7 (53.0 g,
92.8 %) as a light-
yellow viscous oil. 1H NMR (CDC13, 400 MHz) b 4.26 (t, J = 6.8 Hz, 2H), 3.41-
3.63 (m, 2H),3.27
(m, 1 H), 3.02 (s, 3H), 2.92 (m, 1 H), 2.28 (m, 1 H), 2.05 (m, 1 H), 1.83 (m,
2H), 1.50-1.63 (m, 1 H),
1.46 (s, 9H).
Procedure B: Under a nitrogen atmosphere, a solution of triethylamine (460 g,
4.55 mol)
and tert-butyl (R)-3-(2-hydroxymethyl) pyrrolidine-1-carboxylate (the entire
sample from Example
7, Procedure B, 3.03 mol) in toluene (5.20 kg) was stirred and cooled to 5 C.
Methanesulfonyl
chloride (470 g, 4.10 mol) was added slowly, over a 1.25 h, keeping the
temperature below 15
C using ice bath cooling. The mixture was gradually warmed (over 1.5 h) to 35
C, and this
temperature was maintained for 1.25 h, at which point GC analysis indicated
that the reaction
was complete. The mixture was cooled to 25 C, and solids were filtered off
and the filter cake
washed with toluene (1.28 kg). The filtrate was stirred with 10% aqueous
sodium bicarbonate
(4.0 kg) for 15 min, and the phases were allowed to separate for 30 min. The
organic phase
36
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
was then stirred with saturated aqueous sodium chloride (3.9 kg) for 30 min,
and the phases
were allowed to separate for 20 min. The organic phase was combined with
silica gel (160 g)
and stirred for 1 h. Anhydrous sodium sulfate (540 g) was added, and the
mixture was stirred
an additional 40 min. The mixture was then filtered, and the filter cake was
washed with toluene
(460 g). The filtrate was concentrated under vacuum at 50 C for 5 h, and the
resulting oil was
kept under vacuum at 23 C for an additional 8h. This left 798 g of 7, 93%
pure by GC analysis.
Example 8: Synthesis of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate (9)
Procedure A: A solution of tert-butyl (R)-3-
((methylsulfonyloxy)ethyl)pyrrolidine-1-
carboxylate (49.0 g, 167 mmol), sodium iodide (30.0 g, 200 mmol) and 1,2-
dimethoxyethane
(450 ml-) was stirred at 50-60 C for 4 h . The solution was sampled hourly
and analyzed by
HPLC to establish completion of the reaction. Upon completion of reaction, the
solution was
cooled to -10 C, and solid potassium tert-butoxide (32.0 g, 288 mmol) was
added while
maintaining temperature below 0 C. The reaction mixture was warmed to ambient
temperature
and stirred for 1 h. The mixture was sampled hourly and analyzed by HPLC to
establish
completion of the reaction. Upon completion of reaction, the mixture was
filtered through a pad
of diatomaceous earth (25 g dry basis). The cake was washed with 1,2-
dimethoxyethane (100
mL). The combined filtrates were concentrated under vacuum, to yield an orange
oil with
suspended solids. The oil was dissolved in hexanes (400 mL), stirred for 30
min, and filtered to
remove the solids. The organic layer was dried over silica gel (10 g), and
concentrated under
vacuum to give 9 (26.4 g, 82.9 %) as a colorless oil. 1H NMR (CDC13, 400 MHz)
b 5.77 (m, 1 H),
5.10 (dd, J = 1.2 Hz, J = 16 Hz, 1 H), 5.03 (dd, J = 1.2 Hz, J = 8.8 Hz,
1H),3.41-3.59 (m, 2H),
3.29 (m, 1 H), 3.05 (m, 1 H), 2.78 (m, 1 H), 2.01 (m, 1 H), 1.62-1.73 (m, 1
H), 1.46 (m, 9H).
Procedure B: A solution of tert-butyl (R)-3-(2-(methylsulfonyloxy)ethyl)
pyrrol idine-1-
carboxylate (792 g of the product of Example 7, Procedure B, -2.5 mol), sodium
iodide (484 g,
3.27 mol) and 1,2-dimethoxyethane (7.2 L) was stirred at 55 C for 4.5 h under
nitrogen, at
which time GC analysis indicated that the reaction was complete. The solution
was cooled to
<10 C, and solid potassium tert-butoxide (484 g, 4.32 mol) was added in
portions (1.25 h
addition time) while maintaining temperature below 15 C. The reaction mixture
was stirred 1 h
at 5 C, warmed slowly (6 h) to 20 C, and stirred at 20 C for 1 h. The
solution was filtered
through a pad of diatomaceous earth (400 g dry basis). The filter cake was
washed with 1,2-
dimethoxyethane (1.6 kg). The combined filtrates were concentrated under
vacuum, and the
semisolid residue was stirred with heptane (6.0 L) for 2h. The solids were
removed by filtration
(the filter cake was washed with 440 mL of heptane), and the filtrate was
concentrated under
37
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
vacuum at 20 C to give 455 g of 9 (90.7% pure). A sample of this material
(350 g) was
fractionally distilled at 20-23 torr to give 296 g of purified 9 (bp 130-133
C) (>99% pure by GC
analysis).
Example 9: Synthesis of 3-bromo-5-(tetrahydro-2H-pyran-4-yloxy)pyridine (12)
A solution of 5-bromopyridin-3-ol (146 g, 834 mmol), tetrahydro-2H-pyran-4-ol
(128 g,
1250 mmol), and triphenylphosphine (329 g, 1250 mmol) in toluene (2.0 L) was
heated to reflux,
and 750 mL of distillate was removed via a Dean-Stark trap. The reaction
mixture was cooled
to 60 C, and 547 g (1.25 mol) of a 40% (w/w) solution of DEAD in toluene was
added drop-wise
over a 1 hour period. The addition was exothermic with the reactor temperature
at the end of
addition near 95 C. The reaction mixture was stirred at 115 C for 18 h, and
a portion of the
reaction solution was sampled and analyzed by HPLC to establish that the
reaction was
complete. Upon completion of reaction, 500 mL of solvent was removed by
distillation, and the
pot residue was cooled to ambient temperature. This organic layer was washed
with 10%
aqueous sodium hydroxide (2 x 0.50 L) and concentrated under vacuum to produce
a viscous
oil, which was dissolved in 2N hydrochloric acid (1.0 Q. Diatomaceous earth
(100 g) was added
with stirring and the resulting suspension was filtered. The pad was rinsed
with 2N hydrochloric
acid (1.0 L), and the filtrates were combined and extracted with diisopropyl
ether (500 mL). The
diisopropyl ether layer was discarded, and the aqueous layer was treated with
carbon black (10
g) and stirred at 45-50 C for 1 h. The suspension was filtered through a pad
of diatomaceous
earth (25 g). The filtrate was collected, cooled to 5 C, and the pH adjusted
with 50% aqueous
sodium hydroxide (250 mL) to pH=13. The solution was extracted twice with
chloroform (1.0 L,
600 mL), and the chloroform extracts were combined and concentrated under
vacuum to give
12 as a dark red viscous oil/low melting solid (187 g, 87%), which was used
without further
purification. 1H NMR (CDC13, 400 MHz) b 8.29 (s, 1 H), 8.24 (s, 1 H), 7.38 (s,
1 H), 4.52 (m, 1 H),
3.98 (m, 2H), 3.60 (m, 2H), 2.05 (m, 2H), 1.81 (m, 2H).
Example 10: Synthesis of tert-butyl (R)-(E)-3-(2-(5-(tetrahydro-2H-pyran-4-
yloxy)pyridin-3-
yl)vinyl)pyrrolidine-1-carboxylate (13)
A mixture of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate 9 (7.00 g, 35.5
mmol), 3-
bromo-5-(tetrahydro-2H-pyran-4-yloxy)pyridine 12 (10.0 g, 38.8 mmol),
palladium acetate (0.40
g, 1.8 mmol), tricyclohexylphosphine (1.0 g, 3.57 mmol) and
diisopropylethylamine (15 mL) in 1-
methyl-2-pyrroIidinone (130 mL) was stirred at 130 C for 17 h. The reaction
was cooled to
ambient temperature, diluted with water (800 mL) and extracted with ethyl
acetate (2 x 200 mL).
The combined organic extracts were dried over sodium sulfate, concentrated,
and purified by
38
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
silica gel column chromatography using 60-100% ethyl acetate in hexanes. This
product was
further purified on reverse phase HPLC using 0.05% trifluoroacetic acid in
acetonitrile and
0.05% trifluoroacetic acid in water to obtain tert-butyl (R)-(E)-3-(2-(5-
(tetrahydro-2H-pyran-4-
yloxy)pyridin-3-yl)vinyl)pyrrolidine-1-carboxylate (11.0 g) as a gum. 1H-NMR
(CDCI3, 400 MHz):
6 8.41 (s, 1 H), 8.37 (d, J = 2.3 Hz, 1 H), 7.68 (s, 1 H), 6.48 (d, J = 16.1
Hz, 1 H), 6.43 (dd, J =
16.0, 6.4 Hz, 1 H), 4.71-4.66 (m, 1 H), 4.02-3.96 (m, 2 H), 3.68-3.52 (m, 4
H), 3.44-3.34 (m, 1
H), 3.28-3.15 (m, 1 H), 3.09-2.98 (m, 1 H), 2.18-2.04 (m, 3 H), 1.90-1.78 (m,
3 H), 1.48 (s, 9 H)
Example 11: Synthesis of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine (14) hemigalactarate
A solution of tert-butyl (R)-(E)-3-(2-(5-(tetrahydro-2H-pyran-4-yloxy)pyridin-
3-
yl)vinyl)pyrrolidine-1-carboxylate (18 g, 48.13 mmol) in dichloromethane (40
ml-) and
trifluoroacetic acid (40 ml-) was stirred at ambient temperature for 2 h. The
reaction was
concentrated on a rotary evaporator, and the residue was partitioned between
saturated sodium
chloride (50 mL) and chloroform (100 mL). The mixture was basified to pH 9
with 10% aqueous
sodium hydroxide solution. The organic layer was separated and the aqueous
layer extracted
with chloroform (2 x 100 mL). The combined organic layers were dried over
sodium sulfate and
concentrated on a rotary evaporator to give (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-(tetrahydro-2H-
pyran-4-yloxy)pyridine (8.0 g) as a gum. This was dissolved in methanol (100
mL) and
galactaric acid (3.0 g, 14.6 mmol) was added and the mixture was heated to
reflux. This hot
solution was filtered, and filtrate was allowed to cool to ambient
temperature. The crystallized
product was filtered and solid was suspended in 10% water in ethanol (180 mL).
The
suspension was heated to reflux and hot solution was filtered. The filtrate
was allowed to cool to
ambient temperature. Crystallized product was filtered and dried on high
vacuum pump to give
(R)-3-((E)-2-pyrrolidin-3-ylvinyl)-5-(tetrahydro-2H-pyran-4-yloxy)pyridine
hemigalactarate (4.5 g).
MP: 179 C. 1H-NMR (CD3OD, 300 MHz): 6 8.04 (s, 1 H), 8.01 (d, J = 2.2 Hz, 1
H), 7.36 (s, 1
H), 6.46 (d, J = 16.0 Hz, 1 H), 6.21 (dd, J = 16.0, 7.5 Hz, 1 H), 4.65-4.4.54
(m, 1 H), 4.12 (s, 1
H), 3.89-3.83 (m, 2 H), 4.80 (s, 1 H), 3.56-3.33 (m, 4 H), 3.27-3.18 (m, 1 H),
3.12-2.96 (m, 2 H),
2.23-2.14 (m, 1 H), 1.98-1.91 (m, 2 H), 1.88-1.78 (m, 1 H), 1.68-1.58 (m, 2
H); MS (m/z): 275
(M+1).
Example 12: Large scale synthesis of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine (14) mono-L-malate
Under a nitrogen atmosphere, a mixture of 3-bromo-5-(tetrahydro-2H-pyran-4-
yloxy)pyridine (125 g of 85% purity, 410 mmol), (R)-tent-butyl-3-
vinylpyrrolidine-1-carboxylate
39
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(67.4 g, 340 mmol), palladium(II) acetate (8.1 g, 36 mmol), tri-n-
butylphosphine (15 g, 74 mmol),
potassium carbonate (74.0 g, 530 mmol), and DMAC (0.85 L) was stirred and
heated at 130 C,
monitoring for completion of reaction by LCMS. Upon completion of reaction,
the reaction
mixture was cooled to ambient temperature and filtered through a pad of
diatomaceous earth
(50 g dry basis), washing the pad with diisopropyl ether (0.60 Q. The filtrate
was combined with
diisopropyl ether (0.60 L) and de-ionized water (0.50 L) and mixed for 15 min.
The phases were
allowed to separate (15 min), and the organic phase was collected. The aqueous
phase was
extracted with a second portion of diisopropyl ether (0.60 L), using 15 min of
mixing and 15 min
of settling time. The combined diisopropyl ether layers were washed with
deionized water (2 x
0.50 L) and concentrated under reduced pressure to produce a dark red viscous
oil (136 g).
This oil was dissolved in diisopropyl ether (1.40 L) and cooled to around 10
C with an ice bath
before charging 6N hydrochloric acid (0.40 L) via a dropping addition funnel
over a 15 min
period, keeping the temperature below 20 C. The biphasic mixture was warmed
to ambient
temperature (off-gassing occurred as it warmed) and stirred until LCMS
indicated that the
reaction was complete. Upon completion of reaction, the phases were allowed to
separate, and
the organic layer was discarded. The pH of the aqueous layer was adjusted to
pH 5-6 using
10% aqueous sodium hydroxide (0.485 L) and extracted with chloroform (0.25 L).
The
chloroform layer was discarded. The aqueous layer was then adjusted to pH >13
using 10%
aqueous sodium hydroxide (0.075 L) and again extracted with chloroform (0.50
L). The
chloroform extract was concentrated under reduced pressure to yield a red,
viscous oil (55.0 g).
This material was a mixture of the desired (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-tetrahydro-2H-
pyran-4-yloxy)pyridine (-75%) and the corresponding Z (-5%) and "exo" (-20%)
isomers by
NMR analysis. This result was reproducible over multiple runs.
The Z and "exo" impurities were removed from the desired (R)-3-((E)2-
(pyrrolidin-3-
yl)vinyl)-5-tetrahydro-2H-pyran-4-yloxy)pyridine by conversion to the oxalate
salt. A solution of
oxalic acid (53.2 g. 591 mmol) in a mixture of 2-propanol (0.20 L) and de-
ionized water (0.09 L)
was prepared by stirring and heating at 50-55 C (15 min). This solution was
added, over a 5
min period, to a stirred solution of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
tetrahydro-2H-pyran-4-
yloxy)pyridine (82.0 g of 76% pure by HPLC, 299 mmol) in 2-propanol (1.0 L)
held at 70-75 C.
The oxalic acid addition produced an exotherm (4-5 C) that was controlled by
adjusting the rate
of addition. The heating source was removed and the solution was cooled slowly
to 45-50 C
over 45 min. A precipitate formed quickly, beginning around 65-70 C and
becoming heavier as
the resulting suspension cooled. The solids were collected by filtration at 45-
50 C and washed
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
successively with 2-propanol (2 x 0.25 L) and hexanes (2 x 0.20 Q. The tan
solid was air dried
for 2 h, after which it weighed (95 g). NMR analysis indicated that the
content of the Z and "exo"
impurities had each been reduced to <1%. This result was reproducible over
multiple runs.
Material of even greater purity was obtained by recrystallization from
ethanol/water. The
stoichiometry of the salt was 2.3:1 acid/base (see Example 15).
A solution of (R)-3-((E)-2-(pyrrolidinium-3-yl)vinyl)-5-(tetrahydro-2H-pyran-4-
yloxy)pyridinium oxalate (380 g) in de-ionized water (2.6 L) was stirred and
cooled to around 10
C with an ice bath. Aqueous sodium hydroxide (0.40 L of 25%) was added over a
period of 15
min, keeping the temperature below 30 C. Chloroform (1.6 L) was then added,
and the mixture
was stirred vigorously for 20 min and filtered to remove insoluble sodium
oxalate. The layers
were allowed to separate, and the chloroform layer was combined with Silicycle
Si-Thiol (21.6
g). The mixture was stirred and heated at 50-55 C for 3-4 h, cooled to
ambient temperature
and filtered. The filtrate was concentrated under reduced pressure to produce
a light red
viscous oil (221 g). A portion of this free base (216 g) was dissolved in 2-
propanol (1.2 L),
heated to 70-75 C and treated with solid L-malic acid (106 g), using a 2-
propanol rinse (100
mL) to aid transfer. Dissolution of the solid produced an exotherm of 5-7 C
over 3-5 min. The
mixture was kept at 75-78 C for 10 min, to ensure complete dissolution of the
solids, and then
cooled slowly to ambient temperature (90 min). As the temperature approached
65 C, the
solution was seeded with a few crystals of (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-(tetrahydro-2H-
pyran-4-yloxy)pyridine mono-L-malate salt. After stirring at ambient
temperature for 1 h, the
suspension was filtered. The collected solids were washed with 2-propanol (2 x
0.80 L), air
dried for 30 minutes, and vacuum dried at 78 C for 8 h. The resulting off-
white material
weighed 297 g and was >99% pure by HPLC.
Example 13: Procedure for screening for salt forms of (R)-3-((E)-2-(pyrrolidin-
3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine
Test tubes (4 mL), provided with magnetic stir bars, were charged with equi-
milimolar
amounts of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine base and the
acid of interest (neat) and dissolved with 500 pL of either 2-propanol or
acetonitrile with the aid
of heat. If precipitation did not occur upon cooling, isopropyl acetate (100
pL) was added as an
anti-solvent.
If no precipitation occurred, the solvent was evaporated under a nitrogen
stream with
moderate heating and an alternative solvent was tried. Alternative solvents
included acetone,
41
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
ethyl acetate, isopropyl acetate, absolute ethanol, acetonitrile, hexane, tert-
butanol, tert-butyl
acetate, and blends thereof.
The use of alcohols was avoided in the case of sulfonic acids. Isopropyl
acetate was
used cautiously, while the use of acetone and ethyl acetate was discontinued
due to
demonstrated reactivity of the secondary amine function of (R)-3-((E)-2-
pyrrolidin-3-ylvinyl)-5-
(tetrahydro-2H-pyran-4-yloxy)pyridine with these solvents.
Results of these experiments are summarized in Table 1.
Table 1. Acids used in preliminary salt screen
Acid Result
4-Acetamidobenzoic oil
Adipic oil
(1 R,3S)-(+)-Camphoric oil
(1 S)-(+)-1 O-Camphorsulfonic oil
Citric tacky gum
Fumaric oil
D-glucuronic brown gum
Hydrochloric red oil
4-Hydroxybenzoic tacky gum
1-Hydroxy-2-naphthoic brown gum
(Xinafoic)
Maleic Oil
L-Malic Crystals
Malonic Oil
(R)-Mandelic Oil
(S)-Mandelic Oil
Methanesulfonic Oil
4-Methoxybenzoic Oil
Phosphoric Gum
Succinic red oil
L-Tartaric Oil
p-Toluenesulfonic.H20 Oil
As demonstrated in Table 1, finding solid salt forms for (R)-3-((E)-2-
pyrrolidin-3-ylvinyl)-5-
42
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(tetrahydro-2H-pyran-4-yloxy)pyridine was challenging. Reported below are
examples of solids
salts and their syntheses.
Example 14: Preparation of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine mono-L-malate
To a stirred solution of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine (900 mg; 3.28 mmol) in 2-propanol (5 mL), heated to near
boiling, was added L-
malic acid (439.8 mg; 3.28 mmol, neat) in three portions. The solution was
stirred near boiling
for 10 min. Isopropyl acetate (1 mL) was added, heating was discontinued, and
the solution was
seeded while still hot. The solution was allowed to cool to ambient
temperature (22 C) with
stirring whereupon the salt precipitated as a white granular solid. The salt
was re-dissolved by
heating, re-seeded while hot, cooled and allowed to stand at ambient
temperature without
stirring for 24 h. The resulting plate-like crystals were collected by suction
filtration, washed with
isopropyl acetate (5 mL), and dried under nitrogen for 10 min. Further drying
in vacuum oven at
70 C for 1.5 h afforded 1.267 g (94.6 %) of light-yellow crystals (m.p. = 118-
119 C). 'H-NMR
(D20 or d6-DMSO) is consistent with a 1:1 acid: base stoichiometry. DSC
exhibits a single
endotherm with maxima at 119.62 C. DVS shows minimum water uptake up to 80%
R.H. 'H-
NMR (D20, 400 MHz): 6 8.15 (s, 1 H), 8.10 (s, 1 H), 7.58 (s, 1 H), 6.52 (d, 1
H), 6.28 (dd, 1 H),
4.63 (m, 1 H, partially masked by residual H2O resonance), 4.22 (dd, 1 H),
3.88 (m, 2 H), 3.55
(m, 2 H), 3.46 (dd, 1 H), 3.38 (m, 1 H), 3.25 (m, 1 H), 3.11 (m, 1 H), 3.02
(m, 1 H), 2.65 (dd, 1
H), 2.42 (dd, 1 H), 2.20 (m, 1 H), 1.96 (m, 2 H), 1.85 (m, 1 H), 1.68 (m, 2
H). 'H-NMR (d6-
DMSO, 400 MHz): 6 8.20 (s, 1 H), 8.18 (s, 1 H), 7.52 (s, 1 H), 6.55 (d, 1 H),
6.46 (dd, 1 H), 4.68
(m, 1 H), 3.87 (m, 3 H), 3.49 (m, 2 H), 3.40 (dd, 1 H), 3.32 (m, 1 H), 3.18
(m, 1 H), 3.05 (m, 1 H),
2.93 (m, 1 H), 2.51 (dd, 1 H, partially masked by residual DMSO), 2.31 (dd, 1
H), 2.14 (m, 1 H),
1.98 (m, 2 H), 1.80 (m, 1 H), 1.58 (m, 2 H).
Example 15: Preparation of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine oxalate
A warm solution of (1.137 g of 85%, 3.52 mmol corrected for purity) in 2-
propanol (8.5
mL) and water (0.4 mL) was treated with oxalic acid (0.373 g, 4.14 mmol), as a
solid, in one
portion. The resulting mixture was stirred and heated to near reflux. A few
solids began to
precipitate from the hot solution. The mixture was allowed to cool to ambient
temperature. The
off-white solids were filtered (Buchner), washed with 2-propanol (10 mL, 8 mL)
and dried under
vacuum (with an air bleed) at 500 C for 3 h to yield 0.861 g (50.8% yield
based upon a 2.3
oxalate stoichiometry, corrected for purity of the starting material) of an
off-white powder. A
43
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
0.765 g sample of this material was recrystallized from a mixture of 2-
propanol (8 mL) and water
(1.3 mL), heated at reflux. Upon cooling to ambient temperature, the resulting
solids were
filtered (Buchner), washed with 2-propanol (10 mL), dried under vacuum (with
an air bleed) at
50 C for 4 h and then further vacuum dried with an air bleed) at 70 C for 24
h to afford 0.441 g
(57.6% recovery) of an off-white to white solid, mp 180-181 C.
Cacl'd for C16H22N202 . 2.3 C2H204: C, 51.39; H, 5.57; N, 5.82. Found: C,
51.09, 51.24; H, 5.67,
5.66; N, 5.84, 5.92.
1H-NMR (D20, 400 MHz) b 8.23 (s, 1 H), 8.20 (s, 1 H), 7.96 (s,1 H), 6.54 (d, 1
H), 6.40 (dd, 1
H), 4.73 (m, 1 H), 3.84 (m, 2 H), 3.54 (m, 2 H), 3.45 (dd, 1 H), 3.35 (m, 1
H), 3.23 (m, 1 H), 3.12
(m, 1 H), 3.02 (m, 1 H), 2.16 (m, 1 H), 1.96 (m, 2 H),
1.83 (m, 1 H), 1.68 (m, 2 H).
Example 16: Preparation of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine di-p-toluoyl-D-tartrate
To a stirred solution of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine (4.0 g, 15 mmol) in ethanol (12.5 mL) solution, heated to 60
C, was added solid
di-p-toluoyl-D-tartaric acid (5.3 g, 14 mmol). The solution was held at 60 C
for 2-3 min to
ensure complete dissolution of the solids, then the heat source was removed
and the solution
was cooled to 25-30 C over 60 min. The resulting suspension was held at 25 -
30 C for 30
min, and then filtered to collect the solids. The solids were washed with
ethanol (2 X 20 mL), air
dried for 30 min, then dried in a vacuum oven under reduced pressure at 50 C,
until a constant
weight was established, to give (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine di-p-toluoyl-D-tartrate as an off-white solid (6.7 g, 72%).
NNNMR analysis
indicated a 1:1 salt stoichiometry. 1H-NMR (DMSO-d6, 400 MHz) b 8.18 (s, 1 H),
8.15 (s, 1 H),
7.86 (d, 4 H), 7.47 (s, 1 H), 7.32 (d, 4 H), 6.43 (d, 1 H), 6.36 (m, 1 H),
5.67 (s, 2 H), 4.69 (m, 1
H), 3.85 (m, 2 H), 3.49 (m, 2 H), 3.25 (m, 2 H), 3.10 (m, 1 H), 2.88 (m, 2 H),
2.39 (s, 6 H), 1.98
(m, 3 H), 1.60 (m, 3 H).
Biological Assays
Example 17: Radioligand Binding at CNS nAChRs: a4(32 NNR Subtype
Preparation of membranes from rat cortex: Rats (female, Sprague-Dawley),
weighing
150-250 g, were maintained on a 12 h light/dark cycle and were allowed free
access to water
and food supplied by PMI Nutrition International, Inc. Animals were
anesthetized with 70% C02,
and then decapitated. Brains were removed and placed on an ice-cold platform.
The cerebral
44
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
cortex was removed and placed in 20 volumes (weight:volume) of ice-cold
preparative buffer
(137 mM NaCl, 10.7 mM KCI, 5.8 mM KH2PO4, 8 mM Na2HPO4, 20 mM HEPES (free
acid), 5
mM iodoacetamide, 1.6 mM EDTA, pH 7.4); PMSF, dissolved in methanol to a final
concentration of 100 pM, was added and the suspension was homogenized by
Polytron. The
homogenate was centrifuged at 18,000 x g for 20 min at 4 C and the resulting
pellet was re-
suspended in 20 volumes of ice-cold water. After 60 min incubation on ice, a
new pellet was
collected by centrifugation at 18,000 x g for 20 min at 4 C. The final pellet
was re-suspended in
volumes of buffer and stored at -20 C.
Preparation of membranes from SH-EP1/human a4I32 clonal cells: Cell pellets
from 40
10 150 mm culture dishes were pooled, and homogenized by Polytron (Kinematica
GmbH,
Switzerland) in 20 milliliters of ice-cold preparative buffer. The homogenate
was centrifuged at
48,000 g for 20 min at 4 C. The resulting pellet was re-suspended in 20 mL of
ice-cold
preparative buffer and stored at -20 C.
Assay. On the day of the assay, the frozen membranes were thawed and spun at
48,000
x g for 20 min. The supernatant was decanted and discarded. The pellet was
resuspended in
Dulbecco's phosphate buffered saline (PBS, Life Technologies) pH 7.4 and
homogenized with
the Polytron for 6 seconds. Protein concentrations were determined using a
Pierce BCA Protein
Assay Kit, with bovine serum albumin as the standard (Pierce Chemical Company,
Rockford,
I Q.
Membrane preparations (approximately 50 pg for human and 200-300 pg protein
for rat
a4132) were incubated in PBS (50 pL and 100 pL respectively) in the presence
of competitor
compound (0.01 nM to 100 pM) and 5 nM [3H]nicotine for 2-3 h on ice.
Incubation was
terminated by rapid filtration on a multi-manifold tissue harvester (Brandel,
Gaithersburg, MD)
using GF/B filters presoaked in 0.33% polyethyleneimine (w/v) to reduce non-
specific binding.
Tissue was rinsed 3 times in PBS, pH 7.4. Scintillation fluid was added to
filters containing the
washed tissue and allowed to equilibrate. Filters were then counted to
determine radioactivity
bound to the membranes by liquid scintillation counting (22000A Tri-Carb LSC,
Packard
Instruments, 50% efficiency or Wallac Trilux 1450 MicroBeta, 40% efficiency,
Perkin Elmer).
Data were expressed as disintegrations per minute (DPMs). Within each assay,
each
point had 2-3 replicates. The replicates for each point were averaged and
plotted against the
log of the drug concentration. IC50, which is the concentration of the
compound that produces
50% inhibition of binding, was determined by least squares non-linear
regression. Ki values
were calculated using the Cheng-Prussof equation (1973):
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Ki = IC50/ (1 + N/Kd)
where N is the concentration off H]nicotine and Kd is the affinity of nicotine
(3 nM, determined
in a separate experiment).
Example 18: Radioligand Binding at CNS nAChRs: a7 NNR Subtype
Rats (female, Sprague-Dawley), weighing 150-250 g, were maintained on a 12 h
light/dark cycle and were allowed free access to water and food supplied by
PMI Nutrition
International, Inc. Animals were anesthetized with 70% C02, and then
decapitated. Brains
were removed and placed on an ice-cold platform. The hippocampus was removed
and placed
in 10 volumes (weight:volume) of ice-cold preparative buffer (137 mM NaCl,
10.7 mM KCI, 5.8
mM KH2PO4, 8 mM Na2HPO4, 20 mM HEPES (free acid), 5 mM iodoacetamide, 1.6 mM
EDTA,
pH 7.4); PMSF, dissolved in methanol to a final concentration of 100 M, was
added and the
tissue suspension was homogenized by Polytron. The homogenate was centrifuged
at 18,000 x
g for 20 min at 4 C and the resulting pellet was re-suspended in 10 volumes
of ice-cold water.
After 60 min incubation on ice, a new pellet was collected by centrifugation
at 18,000 x g for 20
min at 4 C. The final pellet was re-suspended in 10 volumes of buffer and
stored at -20 C. On
the day of the assay, tissue was thawed, centrifuged at 18,000 x g for 20 min,
and then re-
suspended in ice-cold PBS (Dulbecco's Phosphate Buffered Saline, 138 mM NaCl,
2.67 mM
KCI, 1.47 mM KH2PO488.1 mM Na2HPO4, 0.9 mM CaCI2i 0.5 mM MgCl2,
Invitrogen/Gibco, pH
7.4) to a final concentration of approximately 2 mg protein/mL. Protein was
determined by the
method of Lowry et al., J. Biol. Chem. 193: 265 (1951), using bovine serum
albumin as the
standard.
The binding of [3H]MLA was measured using a modification of the methods of
Davies et
al., Neuropharmacol. 38: 679 (1999), herein incorporated by reference with
regard to such
method. [3H]MLA (Specific Activity = 25-35 Ci/mmol) was obtained from Tocris.
The binding of
[3H]MLA was determined using a 2 h incubation at 21 C. Incubations were
conducted in 48-
well micro-titre plates and contained about 200 pg of protein per well in a
final incubation
volume of 300 L. The incubation buffer was PBS and the final concentration
off H]MLA was 5
nM. The binding reaction was terminated by filtration of the protein
containing bound ligand
onto glass fiber filters (GF/B, Brandel) using a Brandel Tissue Harvester at
ambient
temperature. Filters were soaked in de-ionized water containing 0.33 %
polyethyleneimine to
reduce non-specific binding. Each filter was washed with PBS (3 x 1 mL) at
ambient
temperature. Non-specific binding was determined by inclusion of 50 M non-
radioactive MLA
in selected wells.
46
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
The inhibition off H]MLA binding by test compounds was determined by including
seven
different concentrations of the test compound in selected wells. Each
concentration was
replicated in triplicate. IC50 values were estimated as the concentration of
compound that
inhibited 50 percent of specific [3H]MLA binding. Inhibition constants (Ki
values), reported in
nM, were calculated from the IC50 values using the method of Cheng et al.,
Biochem.
Pharmacol. 22: 3099-3108 (1973).
Selectivity vs. Peripheral nAChRs
Example 19: Interaction at the Human Muscle nAChR Subtype
Activation of muscle-type nAChRs was established on the human clonal line
TE671/RD,
which is derived from an embryonal rhabdomyosarcoma (Stratton et al.,
Carcinogen 10: 899
(1989)). These cells express receptors that have pharmacological (Lukas, J.
Pharmacol. Exp.
Ther. 251: 175 (1989)), electrophysiological (Oswald et al., Neurosci. Lett.
96: 207 (1989)), and
molecular biological profiles (Luther et al., J. Neurosci. 9: 1082 (1989))
similar to the muscle-
type nAChR.
TE671/RD cells were maintained in proliferative growth phase according to
routine
protocols (Bencherif et al., Mol. Cell. Neurosci. 2: 52 (1991) and Bencherif
et al., J. Pharmacol.
Exp. Ther. 257: 946 (1991)). Cells were cultured in Dulbecco's modified
Eagle's medium
(Gibco/BRL) with 10% horse serum (Gibco/BRL), 5% fetal bovine serum (HyClone,
Logan UT),
1 mM sodium pyruvate, 4 mM L-Glutamine, and 50,000 units penicillin-
streptomycin (Irvine
Scientific). When cells were 80% confluent, they were plated to 12 well
polystyrene plates
(Costar). Experiments were conducted when the cells reached 100% confluency.
Nicotinic acetylcholine receptor (nAChR) function was assayed using 86Rb+
efflux
according to the method described by Lukas et al., Anal. Biochem. 175: 212
(1988). On the day
of the experiment, growth media was gently removed from the well and growth
media containing
86 Rubidium chloride (106 NCi/mL) was added to each well. Cells were incubated
at 37 C for a
minimum of 3 h. After the loading period, excess 86Rb+ was removed and the
cells were
washed twice with label-free Dulbecco's phosphate buffered saline (138 mM
NaCl, 2.67 mM
KCI, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, 0.9 mM CaCl2, 0.5 mM MgCI2,
Invitrogen/Gibco, pH.
7.4), taking care not to disturb the cells. Next, cells were exposed to either
100 pM of test
compound, 100 pM of L-nicotine (Acros Organics) or buffer alone for 4 min.
Following the
exposure period, the supernatant containing the released 86Rb+ was removed and
transferred to
scintillation vials. Scintillation fluid was added and released radioactivity
was measured by
liquid scintillation counting.
47
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Within each assay, each point had 2 replicates, which were averaged. The
amount of
86Rb+ release was compared to both a positive control (100 pM L-nicotine) and
a negative
control (buffer alone) to determine the percent release relative to that of L-
nicotine.
When appropriate, dose-response curves of test compound were determined. The
maximal activation for individual compounds (Emax) was determined as a
percentage of the
maximal activation induced by L-nicotine. The compound concentration resulting
in half
maximal activation (EC50) of specific ion flux was also determined..
Example 20: Interaction at the Human Ganglionic nAChR Subtype
The cell line SH-SY5Y is a continuous line derived by sequential subcloning of
the
parental cell line, SK-N-SH, which was originally obtained from a human
peripheral
neuroblastoma. SH-SY5Y cells express a ganglion-like nAChR (Lukas et al., Mol.
Cell.
Neurosci. 4: 1 (1993)).
Human SH-SY5Y cells were maintained in proliferative growth phase according to
routine protocols (Bencherif et al., Mol. Cell. Neurosci. 2: 52 (1991) and
Bencherif et al., J.
Pharmacol. Exp. Ther. 257: 946 (1991)). Cells were cultured in Dulbecco's
modified Eagle's
medium (Gibco/BRL) with 10% horse serum (Gibco/BRL), 5% fetal bovine serum
(HyClone,
Logan UT), 1mM sodium pyruvate, 4 mM L-Glutamine, and 50,000 units penicillin-
streptomycin
(Irvine Scientific). When cells were 80% confluent, they were plated to 12
well polystyrene
plates (Costar). Experiments were conducted when the cells reached 100%
confluency.
Nicotinic acetylcholine receptor (nAChR) function was assayed using 86Rb+
efflux
according to a method described by Lukas et al., Anal. Biochem. 175: 212
(1988). On the day
of the experiment, growth media was gently removed from the well and growth
media containing
86Rubidium chloride (106 pCi/mL) was added to each well. Cells were incubated
at 37 C for a
minimum of 3 h. After the loading period, excess 86Rb' was removed and the
cells were
washed twice with label-free Dulbecco's phosphate buffered saline (138 mM
NaCl, 2.67 mM
KCI, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, 0.9 mM CaCI2, 0.5 mM MgC12,
Invitrogen/Gibco, pH
7.4), taking care not to disturb the cells. Next, cells were exposed to either
100 pM of test
compound, 100 pM of nicotine, or buffer alone for 4 min. Following the
exposure period, the
supernatant containing the released 86Rb+ was removed and transferred to
scintillation vials.
Scintillation fluid was added and released radioactivity was measured by
liquid scintillation
counting
Within each assay, each point had 2 replicates, which were averaged. The
amount of
86Rb+ release was compared to both a positive control (100 pM nicotine) and a
negative control
48
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(buffer alone) to determine the percent release relative to that of L-
nicotine.
When appropriate, dose-response curves of test compound were determined. The
maximal activation for individual compounds (Emax) was determined as a
percentage of the
maximal activation induced by L-nicotine. The compound concentration resulting
in half
maximal activation (EC50) of specific ion flux was also defined.
Example 21: Novel Object Recognition
Memory was assessed by using a three-trial novel object recognition test
(Luine et al.,
Pharm. Biochem. Behav. 74, 213-220 (2002)). On the first day (exploratory
trial), rats were
allowed to explore an open arena (44.5 x 44.5 x 30.5 cm) for 6 min. On the
second day
(acquisition trial), rats were allowed to explore the same arena in the
presence of two identical
objects (both object A) for 3 min. On the third day (retention or recall
trial), performance was
evaluated by allowing the same animal to re-explore the arena for 3 min in the
presence of two
different objects: the familiar object A and a novel object B. An inter-trial
interval of 24 h was
imposed between the three NOR trials. Recognition memory was assessed by
comparing the
time spent exploring a novel (object B) versus a familiar (object A) object
during the recall trial.
Recognition index was assessed for each animal and expressed as a ratio ((time
B / time A +
time B) x 100).
Example 22: Radial Arm Maze
Working memory was assessed in a radial arm maze (RAM) task. The RAM task was
conducted using an automated eight-arm maze (Med Associates, Inc.) The maze
was located
on a circular table approximately 88 cm above the floor with overhead lighting
in a dedicated
testing ambient and large, high contrast geometric shapes on the wall.
Furthermore, additional
visual cues were located at the hub entry into each arm, above each the food
hopper and on the
ceiling. The central platform measured 30.5 cm in diameter with eight arms (9
cm W x 45.7 cm L
x 16.8 cm H) radiating from it. Automatic guillotine doors were located at the
entrance to each
runway with a pellet receptacle at the distal end of each arm. White noise
will be audible during
all training and testing procedures. Activity on the maze was monitored by
tracking quantitative
activity (generated by infra-red beam breaks) on the computer interface and
monitor screen.
Following the baseline assessment and after re-attainment test session
criterion, animals
were assessed for their sensitivity to chemically-induced cognitive impairment
using the
muscarinic antagonist scopolamine (0.2-0.4 mg/kg; s.c.). A dose of scopolamine
was
determined for each animal based on the minimum dose that produced significant
and reliable
cognitive impairment. Scopolamine was administered 0.5h prior to the
acquisition phase trial
49
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
whereas, (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine hemi-galactarate
(0.03 mg/kg; p.o.) was administered 0.5 h prior to the start of the recall (or
test) phase trial. In
the acquisition trial, one randomly selected arm was blocked with a Plexiglas
barrier situated
just inside the arm, behind the hub door. The animal was placed in the central
hub of the maze
with doors down. After approximately 10 sec, doors to the 7 available arms
were raised. The
first entry to each open arm was reinforced with a sucrose food pellet. The
session ended after
all 7 available arms were visited or 5 min elapsed. The order of arms visited,
reinforcers
received, errors (re-entries), time to complete the task, the number of
entries and time required
to enter 7 available arms and consume food reinforcer were recorded. In the
recall trial, all 8
arms were available, however, only the first visit to the previously blocked
arm (i.e., the arm that
was blocked during the acquisition trial) was reinforced. The session ended
once the previously
blocked arm was visited and the reinforcer was consumed or 5 min elapsed. For
the recall trial,
re-entry errors, the number of (incorrect) arms entered prior to choosing the
arm that was
blocked during the acquisition trial and the time taken to complete the trial
was recorded. The
delay between the acquisition and test phase trials was 24 h .
Example 23: CYP Inhibition Studies
Inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 catalytic activity by
(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
slat thereof was
assessed using a fluorogenic CYP assay. Probe substrates which fluoresce upon
CYP
catalyzed oxidation were used to evaluate the degree of inhibition of the test
substrate. A single
concentration of each probe substrate (at approximately the apparent Km value)
and two
different concentrations of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine
hemigalactarate (2 and 20 pM) were tested in duplicate. Fluorescence intensity
at selected
wavelengths was used as a measure of enzyme activity. Decreased fluorescence
in the
presence of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine or a sat
thereof was an indication of inhibition. Positive controls (known inhibitors)
Were run
concurrently to demonstrate method control and CYP activity. Duplicate samples
were run
alongside the positive and negative controls. Incubation of test samples was
performed at 37
C. Experimental parameters are outlined in Table 2.
Table 2: Experiment conditions for fluorescence CYP inhibition assays
CYPIA2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
Enzyme
amount 1 2 2 3 1
(pmol/well)
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
Probe
Substrate 3 M CEC 75 M MFC 100 M MFC MAMC 15 M BFC
KP04 pH 7.4 0.1 M 0.05M 0.05 M 0.1 M 0.1 M
NADPH conc. 1 mm 1 MM 1 MM 0.06 mM 1 mm
Incubation 20 min 50 min 40 min 35 min 30 min
time
Ex/Em X (nm) 405/460 405/530 405/530 390/460 405/530
Gain 20 40 30 10 50
Reference Furafyllin Sulfaphenaz Tranylcyprom Quinidine Ketoconazo
inhibitor e ole ine le
Expected 15 - 25 3-5 3-5 3-6 4-15
signal/noise
1C50 ( M) for
reference - 1 -1 -6 -0.01 -0.06
inhibitor
CEC = 3-Cyano-7-ethoxy-coumarin
MFC = 7-methoxy-4-trifluoromethyl-coumarin
MAMC = 7-methoxy-4-(aminomethyl)-coumarin
BFC = 7-bensyloxy-4-trifluoromethyl-coumarin
Summary of Biological Data
In vitro pharmacology
A summary of the in vitro primary pharmacology data for (R)-3-((E)-2-
(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof is presented
in Table 3 and
discussed in detail below.
Primary pharmacology and selectivity: The capacity of (R)-3-((E)-2-(pyrrolidin-
3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof to bind to
a4(32 receptors was
determined with receptor binding inhibition assays using human recombinant
a4(32 receptors
expressed in SH-EP1 cellular membranes and rat native a4(32 receptors in rat
cortical
membranes.
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
inhibited the binding of [3H]-nicotine to human recombinant a4132 nicotinic
receptors with a K; of
2 nM and [3H]epibatidine to rat native a4(32 receptors with a K; of 4 nM.
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
inhibited the binding of [3H]methyllycaconitine (MLA) to rat native 0
receptors in rat
hippocampal membranes with a K; of >10000 nM. (R)-3-((E)-2-(Pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a salt thereof also displayed reduced
affinity for human
native ganglion-type nicotinic receptors (likely a3(34), inhibiting the
binding of [3H]epibatidine to
51
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
receptors in SH-SY5Y membranes with a K, of 3400 nM, and reduced affinity for
human native
muscle-type nicotinic receptors (likely a1(31y5), inhibiting the binding of
[3H]epibatidine to
receptors in TE-671 membranes with a K; of 25000 nM.
Table 3. Summary of (R)-3-(2-(pyrrolidin-3-yl)vinyl)-5-((tetrahydro-2H-pyran-4
yl)oxy)pyridine, or a salt thereof, in vitro pharmacology
Target affinity and activation
............. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . ................ . . . . .
.............................. ........... ......... . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . .
......................................
Rat cortex binding K; 4 nM
.... ....... ........................................................... ....
... ....................... ... ... ...
.......................................
.................................................. . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . .
Human recombinant (SH-EP 1) a4132 binding K; 2 nM
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
............................... . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .............. ........................... . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rat hippocampus (a7, K; >10000 nM
. . . . ................................................ . . . . . . .......
................................ .. . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . ............ ........................................ . . . . . . .
. . ................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . .
Human ganglionic (SH-SY5Y), K; 3400 nM
...... ....... .. .................................................... ...
...... ........................ . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.............. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . .
Human (TE671/RD) muscle, K; 25 pM
Human recombinant (SH-EP 1) a432 EC50, 0.1 pM, 76%
Emax (Ca flux)
Human ganglionic (SH-SY5Y), EC50, Emax (Ca 11 pM, 13%
flux)
Human (TE671/RD) muscle, EC50, Emax (Ca 13 pM, 37%
flux)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . ..... .... ...
............... .................................................
....................................
Multiple receptor screening assay Only nicotinic
Cellular efficacy: The aim of these studies was to determine functional
activity of (R)-3-
((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt
thereof at human
recombinant a4R2 receptors. (R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine or a salt thereof is an a432 nicotinic agonist activating the
receptor with an EC50
of 0.1 pM and an Emax of 76% in relation to 10 pM nicotine in a calcium flux
assay with SH-
EP1/human a4132 cells following 24-h incubation at 29 C.
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
was tested in ganglion and muscle-type nicotinic receptor ion flux assays to
examine functional
selectivity. In Ca" efflux assays, (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine or a salt thereof has an EC50 of 11 pM and an Emax of 13% at
human native
ganglion receptors in SH-SY5Y cells, an EC50 of 13 pM and an Emax of 37% at
human native
muscle receptors in TE-671 cells.
In vitro secondary pharmacology: Multiple receptor screening assay
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
was tested for selectivity against a panel of 65 receptors. At a single
concentration of 10 pM,
52
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof inhibited
the binding of labelled ligand only to neuronal nicotinic receptors ((x-BnTx
insensitive) with 99%
inhibition.
Inhibition of hERG
The IC50 for the inhibition of hERG (human HEK-239 cells) by (R)-3-((E)-2-
pyrrolidin-3-
ylvinyl)-5-(tetrahydro-2H-pyran-4-yloxy)pyridine or a salt thereof was
determined to be 84 pM.
In vivo pharmacology
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
improved long-term visual episodic/declarative memory as assessed by novel
object recognition
(NOR) task following oral dosing in normal rats. The results of these studies
are presented in
Figure 1. The recognition index of the vehicle-treated group 24 h after the
acquisition trial was
50 0.5% demonstrating the inability of this group to recognize the familiar
object after this delay
(left panel). By contrast, animals treated with (R)-3-((E)-2-(pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a salt thereof exhibited recognition
indexes of 71 2% at the
0.04 pmol/kg dose level and 61 3% and the 1.1 pmol/kg dose level (left panel).
In a follow-up
NOR study (experimental procedures were identical as used in the first NOR
study), the
minimum effect dose (MED) level for (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine or a salt thereof was determined to be 0.004 pmol/kg (right
panel) suggesting that
the rats are able to recognize the familiar object at all doses levels tested.
In the two "recall
only" sessions; subset of animals were orally dosed with water on day 1 (i.e.,
exploratory
session) and day 2 (i.e., acquisition session) and then orally dosed either
with 1.1 pmol/kg (R)-
3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt
thereof (left panel) or
0.04 pmol/kg (right panel) on day 3 (i.e., recall session). Even following a
single oral
administration, (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine or a salt
thereof demonstrated pro-cognitive effects at these two dose levels. At both
dose levels, (R)-3-
((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt
thereof exhibited
recognition indexes significantly above controls, indicating recognition of
the familiar object
following acute dosing. In the Figure, the dashed line at 65% denotes
subjective criteria for
biological cognitive enhancing activity. *P < 0.05.
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
was evaluated for its duration of effect in the NOR task in normal rats. The
results of these
studies are presented in Figure 2. The recognition index of the vehicle-
treated group at 0.5 h
following dosing on the recall trial was 52 0.8% demonstrating the inability
of this group to
53
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
recognize the familiar object after this delay. By contrast, animals treated
with (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof
(0.004 pmol/kg: oral)
exhibited recognition indexes of 72 2% at 0.5h, 70 3% at 6h and 70 4% at 8h
suggesting that
rats are able to recognize the familiar object for up to 8h after dosing. In
the Figure, the dashed
line at 65% denotes subjective criteria for biological cognitive enhancing
activity (*P < 0.05).
On the basis of these studies, a likely pharmacological effect is possible
when dosing
(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof over a
wide range, including relatively low dose levels. One embodiment of the
present invention
relates to dosing (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-
yloxy)pyridine or a
pharmaceutically acceptable salt thereof in oral doses as low as about 0.004
pmol/kg. One
embodiment of the present invention relates to an oral dose of less than 100
mg, preferably less
than 50 mg, more preferably less than 10 mg, and most preferably less than 1
mg. These
effective doses typically represent the amount administered as a single dose,
or as one or more
doses administered over a 24 h period.
Radial Arm Maze (RAM) Studies
In a second cognitive assay, (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine or a salt thereof attenuated cognitive deficits, induced by
scopolamine, in an
animal model of working memory. Results of these experiments are illustrated
in Figure 3.
During the acquisition trial, rats were allowed access to 7 of the eight arms
whereas, in the test
trial, all 8 arms were available, however, only the first visit to the
previously blocked arm (i.e.,
the arm that was blocked during the acquisition trial) was reinforced.
Scopolamine (0.3 0.1
mg/kg; s.c.) was administered 0.5h prior to the acquisition trial, and (R)-3-
((E)-2-(pyrrolidin-3-
yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt thereof (0.03 mg/kg or
0.1 pmol/kg; p.o.)
was administered 0.5 h prior to the test trial. (R)-3-((E)-2-(Pyrrolidin-3-
yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a salt thereof was able to reverse
scopolamine-induced
cognitive deficits (*P < 0.05).
Human Cytochrome P450 (CYP) inhibition, induction, transport, and drug-drug
interaction potential
A CYP450 inhibition assay using fluorescent substrates and recombinant enzymes
showed no evidence of inhibition by (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-
yloxy)pyridine or a salt thereof of the 5 major CYPs (IC50 >20 pM, Table 4).
In addition, no
evidence of time-dependent inhibition of CYP3A4, CYP2D6, CYP2B6, CYP2C9, or
CYP1A2
was observed. No PXR (pregnane X receptor) activation by (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-
54
CA 02744191 2011-05-19
WO 2010/065447 PCT/US2009/066083
5-(tetrahydropyran-4-yloxy)pyridine was observed up to 10 NM, thus the risk
related to induction
of P450s is believed to be negligible.
Table 4
CYP inhibition IC50 (p.M)
CYP mediated metabolism
1A2 > 20
3A4 > 20
2C9 > 20
2C19 > 20
2D6 > 20
(R)-3-((E)-2-(Pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a
salt thereof
exhibits low hepatic turnover rate in human liver microsomes or hepatocytes.
Preliminary
phenotyping data suggested that both CYP2D6 and FMO3 contributed to the
metabolism of (R)-
3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or a salt
thereof. In addition,
renal clearance was expected to be the major elimination route, contributing
more than 50% of
the total clearance in human. Therefore any variation of (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine or a salt thereof metabolism in human due to
CYP
polymorphism is expected to be less than 2 fold due to the significant renal
clearance and low
hepatic clearance.
Test compounds for the experiments described herein were employed in free or
salt
form, and, if not otherwise stated, the test compound is (R)-3-((E)-2-
(pyrrolidin-3-yl)vinyl)-5-
(tetrahydropyran-4-yloxy)pyridine hemigalactarate.
The specific pharmacological responses observed may vary according to and
depending
on the particular active compound selected or whether there are present
pharmaceutical
carriers, as well as the type of pharmaceutical composition and mode of
administration
employed, and such expected variations or differences in the results are
contemplated in
accordance with practice of the present invention.
Although specific embodiments of the present invention are herein illustrated
and described
in detail, the invention is not limited thereto. The above detailed
descriptions are provided as
exemplary of the present invention and should not be construed as constituting
any limitation.
Modifications will be obvious to those skilled in the art, and all
modifications that do not depart from
the spirit of the invention are intended to be included with the scope of the
appended claims.
